{"gene":"CCL19","run_date":"2026-06-09T22:57:17","timeline":{"discoveries":[{"year":2000,"finding":"CCL19 (ELC) is expressed by T zone stromal cells (which co-express SLC/CCL21) and by CD8+ dendritic cells in secondary lymphoid organs; this co-expression was established by double in situ hybridization and bone marrow reconstitution experiments in wild-type mice, with both genes deleted in plt/plt mice.","method":"Double in situ hybridization, bone marrow reconstitution, genetic deletion (plt/plt mouse)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal localization by two orthogonal methods (double ISH + BM reconstitution) replicated across the plt/plt genetic model","pmids":["11070085"],"is_preprint":false},{"year":2001,"finding":"Perivascular CCL19 is transcytosed to the luminal surface of high endothelial venules (HEVs) and enables CCR7-mediated T cell arrest and homing to lymph nodes; injected CCL19 in plt/plt mice restored T cell trafficking to draining lymph nodes as efficiently as CCL21.","method":"In situ hybridization, immunohistochemistry (cytoplasmic vesicle localization), footpad injection with lymph node trafficking assay in plt/plt mice","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (ISH, IHC, in vivo rescue in genetic model) in a single study with clear functional readout","pmids":["11342595"],"is_preprint":false},{"year":2001,"finding":"CCL19 induces rapid, concentration-dependent internalization of CCR7 on T lymphocytes, markedly reducing subsequent responsiveness to re-stimulation; in contrast, CCL21 does not induce CCR7 internalization, establishing a fundamental functional difference between the two CCR7 ligands.","method":"Flow cytometry receptor surface expression, functional re-stimulation assays","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct receptor trafficking assay with two orthogonal readouts (surface expression + functional desensitization), single lab","pmids":["11745346"],"is_preprint":false},{"year":2000,"finding":"CCL19 acts as a functional ligand for CCX-CKR (later ACKR4/CCX-CKR), in addition to CCR7; CCX-CKR binds CCL19 with high affinity (IC50 <15 nM) and also binds CCL21 and TECK, identified by stalk-immobilized chemokine adhesion assay and radiolabeled competition binding.","method":"Stalkokine adhesion assay, radiolabeled ligand binding and competition with >80 chemokines","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — in vitro binding reconstitution with radiolabeled ligand and competition across >80 chemokines; comprehensive profiling","pmids":["10706668"],"is_preprint":false},{"year":2000,"finding":"DC migration from skin epidermis to lymph nodes requires CCL19: in vitro cysteinyl leukotrienes (LTC4, LTD4) promoted optimal chemotaxis to CCL19 (but not other chemokines), and in vivo antagonism of CCL19 prevented DC egress from the epidermis, placing CCL19 downstream of MRP1-transported LTC4 in a defined DC trafficking pathway.","method":"In vitro chemotaxis assay, MRP1-/- mice, exogenous LTC4/LTD4 rescue, in vivo CCL19 antagonism","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout combined with pharmacological rescue and in vivo antagonism, multiple orthogonal approaches in a single study","pmids":["11114332"],"is_preprint":false},{"year":2002,"finding":"Ectopic expression of CCL19 in pancreatic islets induces infiltrates composed of lymphocytes and DCs containing high endothelial venules; CCL19 (like CCL21 but not CXCL12) induces LTα1β2 expression on naive CD4 T cells, suggesting CCL19 drives lymphoid neogenesis partly through induction of lymphotoxin.","method":"CCL19 transgenic mouse model, histopathology, LTα1β2 expression assays, LTβR-Fc antagonist treatment","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — transgenic in vivo model with pharmacological antagonist rescue, multiple cell and molecular readouts, comparative ligand analysis","pmids":["12077273"],"is_preprint":false},{"year":2003,"finding":"CCL19/CCL21-triggered CCR7 signal transduction and DC migration require prostaglandin E2 (PGE2) for coupling: PGE2 enables CCR7 to activate PI3K-mediated Akt phosphorylation and intracellular Ca2+ mobilization; migration depends on PLC and intracellular Ca2+ flux but not PI3K.","method":"Phosphorylation assays (PI3K/Akt), intracellular calcium mobilization, pharmacological inhibitors (PLC, PI3K), DC migration assay","journal":"Blood","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro biochemical assays with multiple pathway inhibitors, two orthogonal signaling readouts (Ca2+ and Akt), single lab","pmids":["14592837"],"is_preprint":false},{"year":2005,"finding":"CCL19 (signaling through CCR7) induces maturation of activated/migratory DCs (upregulation of costimulatory molecules and proinflammatory cytokines) and programs them for Th1 induction; only CCR7-high migrating DCs (not resting lymph-node-resident DCs) respond to CCL19 with cytokine production; plt/plt DCs (lacking CCL19 and CCL21) display only partially mature phenotype in vivo.","method":"Alphaviral expression cloning, DC-T cell coculture proliferation assay, flow cytometry (maturation markers), cytokine ELISA, plt/plt genetic model","journal":"Immunity","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (expression screen, coculture, genetic model), replicated in vitro and in vivo","pmids":["15845453"],"is_preprint":false},{"year":2002,"finding":"CCL19 rapidly induces marked dendritic extension (within 30 min) in mature but not immature DCs via Rac and/or Cdc42 GTPases (not Rho/ROCK), as shown by complete blockade with Clostridium difficile toxin B but not Y-27632; CCL21 fails to induce rapid dendritic extension.","method":"Murine DC morphology assay, pharmacological inhibitors (toxin B, Y-27632), time-course imaging","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — pharmacological dissection with two inhibitors, clear differential CCL19 vs CCL21 response, single lab","pmids":["12200351"],"is_preprint":false},{"year":2004,"finding":"CCL19 is produced by neutrophils when stimulated with LPS or TNFα; neutrophil-derived CCL19 is biologically active, inducing chemotaxis of DCs and rapid integrin-dependent adhesion of CCR7-expressing lymphocytes to ICAM-1, as demonstrated by neutralizing antibody blockade.","method":"Neutrophil culture with LPS/TNFα, chemotaxis assay, integrin adhesion assay, neutralizing antibody blockade","journal":"European journal of immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional chemotaxis and adhesion assays with neutralizing antibody confirmation, single lab, two orthogonal readouts","pmids":["11449350"],"is_preprint":false},{"year":2006,"finding":"CCX-CKR (ACKR4) mediates progressive scavenging and degradation of CCL19: after CCL19 uptake, CCR7 rapidly desensitizes and cannot sustain further scavenging, but CCX-CKR maintains enhanced sequestration activity and degrades internalized CCL19. CCX-CKR uses a caveolin-1-dependent (not clathrin/β-arrestin-dependent) endocytic route distinct from CCR7.","method":"Transfected HEK293 cells, radiolabeled CCL19 internalization and degradation assay, siRNA/caveolin-1 overexpression, β-arrestin knockdown","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted receptor system with radiolabeled ligand, multiple mechanistic inhibitors, and mechanistic distinction between two receptors in one study","pmids":["16791897"],"is_preprint":false},{"year":2008,"finding":"Arrestin 3 (β-arrestin 3) specifically mediates CCR7 internalization following CCL19 binding but is not required for CCL21-induced internalization; CCR7/CCL19 internalization and migration to CCL19 both require arrestin 3, whereas CCR7/CCL21 internalization and migration to CCL21 are arrestin-independent.","method":"siRNA knockdown of arrestin 2 and 3, arrestin 2-/-/arrestin 3-/- MEFs reconstituted with arrestin-GFP constructs, flow cytometry, immunofluorescence microscopy, Transwell migration assay","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 1 / Strong — genetic and biochemical reconstitution (null MEFs + rescue), multiple orthogonal assays (receptor internalization + migration), two-ligand comparison","pmids":["18802075"],"is_preprint":false},{"year":2009,"finding":"CCL19 is a specific ligand for CRAM (CCRL2), an atypical chemokine receptor on B lymphocytes; CRAM binds CCL19 with affinity similar to CCR7 but does not induce calcium mobilization or chemotaxis; instead, CRAM constitutively recycles via clathrin-coated pits and internalizes CCL19, functioning as a scavenger receptor.","method":"Radioactive binding assay, calcium mobilization assay, migration assay, internalization assay with anti-CRAM antibodies, CRAM-expressing transfected cells","journal":"Immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding with radiolabeled ligand, negative functional assays, internalization assay; single lab but multiple methods","pmids":["20002784"],"is_preprint":false},{"year":2010,"finding":"CCL21 is sufficient for DC migration, maturation, and T cell priming in vivo; CCL19 alone is not required: CCL19-deficient mice with intact CCL21 show normal DC frequencies, localization, skin DC migration, maturation, and T cell priming, whereas combined CCL19/CCL21 deficiency reproduces the CCR7-/- phenotype.","method":"CCL19-deficient mice (genetic knockout), flow cytometry, skin DC migration assay, T cell priming assay, lymph node histology","journal":"European journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — clean genetic knockout with multiple orthogonal readouts (migration, maturation, priming) and comparative analysis with double-knockout","pmids":["20039103"],"is_preprint":false},{"year":2010,"finding":"CCL21-stimulated DC chemotaxis in 3D gradients is more potent than CCL19 at high gradient concentrations; at small gradients (≤60 nM/mm) DCs respond similarly to both ligands. When exposed to equal/opposing gradients, DCs preferentially migrate toward CCL21 over CCL19, even when matrix binding of CCL21 is prevented.","method":"Microfluidic 3D gradient device with defined chemokine gradients, quantitative DC chemotaxis tracking","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — quantitative 3D migration assay, systematic gradient comparison, single lab","pmids":["21422278"],"is_preprint":false},{"year":2012,"finding":"CCR7/CCL19 signaling upregulates ERK5 and subsequently the transcription factor KLF2 and EDG-1 (S1P receptor 1) expression in T cells; ERK5-deficient T cells (Lck-Cre/ERK5-flox) fail to upregulate EDG-1 in response to CCL19, and show impaired migration toward EDG-1 ligands, defining a CCL19→CCR7→ERK5→KLF2→EDG-1 axis controlling T cell lymph node egress.","method":"Signaling assays (ERK5 phosphorylation, KLF2 and EDG-1 expression), conditional knockout mice (ERK5flox/flox/Lck-Cre), Transwell migration assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — conditional genetic knockout rescue experiments combined with molecular pathway analysis across two cell types (cell line and primary T cells)","pmids":["22334704"],"is_preprint":false},{"year":2015,"finding":"The solution structure of CCL19 contains a canonical chemokine fold; NMR chemical shift mapping shows that the N-termini of CCR7 and PSGL-1 have overlapping and competitive binding sites on CCL19, suggesting PSGL-1 enhances T cell recruitment by co-presentation of CCL19.","method":"NMR solution structure determination, NMR chemical shift mapping, competitive binding assay","journal":"Biochemistry","confidence":"High","confidence_rationale":"Tier 1 / Moderate — NMR structure with functional binding site mapping and competitive inhibition, single lab","pmids":["26115234"],"is_preprint":false},{"year":2016,"finding":"ACKR4 on stromal cells (keratinocytes and dermal lymphatic endothelial cells) scavenges dermal CCL19 during cutaneous inflammation to enable APC egress from skin; Ackr4-deficient mice show impaired Langerhans cell egress and DC accumulation in lymph nodes, and this phenotype is fully rescued by genetic deletion of Ccl19, establishing that ACKR4 functions specifically by scavenging CCL19 (not CCL21) under inflammatory conditions.","method":"Ackr4-/- mice, Ccl19-/- genetic rescue (double knockout), flow cytometry of skin APC populations, ACKR4-dependent chemokine scavenging in situ","journal":"Journal of immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic double-knockout rescue experiment with multiple flow cytometric readouts, demonstrates specificity for CCL19 over CCL21","pmids":["26976955"],"is_preprint":false},{"year":2016,"finding":"CCL19 treatment of resting CD4+ T cells activates NF-κB, PI3K/Akt, ERK, and p38 signaling pathways; HIV integration in CCL19-treated resting T cells requires NF-κB signaling (HIV LTR NF-κB mutants show 40-fold reduced integration), and CCL19 stabilizes HIV integrase via a JNK-dependent Pin1 interaction, reducing proteasomal degradation.","method":"Phosphorylation assays (Akt, ERK, NF-κB, p38), pathway inhibitors (PI3K, MEK, JNK, NF-κB), HIV infection with NF-κB-site mutant virus, Alu-LTR/2-LTR qPCR, Pin1 co-immunoprecipitation","journal":"Retrovirology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple pharmacological inhibitors and mutant virus, Co-IP for Pin1 interaction, single lab","pmids":["27459960"],"is_preprint":false},{"year":2019,"finding":"Biased signaling between CCL19 and CCL21 through CCR7 is determined by the chemokine core domains (not the N-termini): chimeric ligands with swapped N-termini retain original signaling properties, while swapping core domains transfers signaling bias. Extracellular loop 2 (ECL2) of CCR7 interacts differentially with the two ligands and is central to signaling bias; lysine K130 (TM3) selectively regulates G protein (but not β-arrestin-2) signaling.","method":"BRET-based signaling assays (G protein, β-arrestin recruitment), chimeric CCL19/CCL21 ligands, CCR7 mutagenesis screen, Transwell migration assay, in silico modeling","journal":"Frontiers in immunology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — structure-function mutagenesis with reconstituted BRET assays and chimeric ligands, multiple signaling pathways assessed; single lab","pmids":["31572374"],"is_preprint":false},{"year":2023,"finding":"CCR7 acts as both a sensor and a sink for CCL19: upon CCL19 exposure, DCs internalize CCR7-CCL19 complexes as part of canonical GPCR desensitization, and this internalization acts as an effective chemokine sink that dynamically shapes CCL19 gradients. This self-generated gradient mechanism drives collective DC migration, enables long-range guidance, adapts to environmental geometry, and provides guidance cues for co-migrating cells.","method":"Live-cell imaging, mathematical modeling of chemokine gradients, experimental CCL19 gradient assays, DC migration tracking","journal":"Science immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — combination of quantitative experimental migration data and mechanistic mathematical modeling, multiple orthogonal readouts, novel dual-function mechanism demonstrated","pmids":["37656776"],"is_preprint":false},{"year":2006,"finding":"CCL19 promotes proinflammatory cytokine production (including MMP and tissue factor) in macrophages and VEGF/angiopoietin-I in fibroblasts via CCR7; in atherosclerosis, CCL19 and CCL21 upregulate MMP and tissue factor in macrophages, potentially contributing to plaque destabilization.","method":"In vitro macrophage and fibroblast stimulation, ELISA for MMP/tissue factor/VEGF/Ang-I, CCR7-expressing cell lines","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional in vitro stimulation assays with protein readouts, single lab, multiple cell types","pmids":["17170367"],"is_preprint":false},{"year":2014,"finding":"CCL19/CCR7 signaling promotes monocyte adhesion to endothelial cells via CCR7; CCR7-neutralizing antibody abolishes both CCL19- and CCL21-induced monocyte-to-HUVEC migration and CCL19-induced adhesion, placing CCR7 as the mediator of CCL19-driven atherogenic monocyte trafficking.","method":"Cell adhesion assay (monocyte to HUVEC), CCR7-neutralizing antibody blockade, cell migration assay","journal":"Arteriosclerosis, thrombosis, and vascular biology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional cell adhesion/migration assay with receptor neutralization, single lab","pmids":["24990231"],"is_preprint":false},{"year":2013,"finding":"CCL19/CCR7 upregulates heparanase expression in lung adenocarcinoma A549 cells via the transcription factor Sp1; Sp1 binds the heparanase promoter (confirmed by chromatin immunoprecipitation), and CCL19-induced invasion is dependent on this CCR7→Sp1→heparanase pathway.","method":"Western blot, RT-PCR, CCR7 blockade, Sp1 inhibition, chromatin immunoprecipitation, Transwell invasion assay","journal":"Tumour biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — ChIP for direct promoter binding, pathway inhibition at multiple nodes, invasion readout; single lab","pmids":["23649655"],"is_preprint":false},{"year":2010,"finding":"CCL19/CCL21-CCR7 signaling in CLL cells promotes migration via PI3K and Rho/ROCK pathways (but not MAPKs), while CCR7-mediated survival requires ERK, JNK, and PI3K; activation of Akt, RhoA/ROCK/MLC and MAPK were confirmed biochemically.","method":"Pharmacological inhibitors, dominant-negative and constitutively active PI3K/RhoA mutants, pull-down assay (Rho activation), immunoblotting, chemotaxis and apoptosis assays","journal":"Experimental hematology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic dominant-negative constructs plus pharmacological inhibitors, multiple biochemical and functional readouts; single lab","pmids":["20488224"],"is_preprint":false},{"year":2010,"finding":"CCL19-induced CCR7 signaling leads to increased phosphorylation of Akt in resting CD4+ T cells; PI3K inhibition partially suppresses IFN-γ secretion from HBV-responsive T cells stimulated with CCL19, placing PI3K downstream of CCL19/CCR7 in T cell activation.","method":"Phosphorylation assays (Akt), PI3K inhibitor (LY294002), IFN-γ ELISA, CCR7 knockdown","journal":"Journal of gastroenterology","confidence":"Low","confidence_rationale":"Tier 3 / Weak — pharmacological inhibition with single pathway readout, single lab; full paper PMID 34218330 (2021 publication date actually)","pmids":["34218330"],"is_preprint":false},{"year":2010,"finding":"CRAM (CCRL2) expressed at high levels on CLL B cells competitively reduces CCL19 availability for CCR7, blunting CCR7-dependent MAP-kinase phosphorylation, intracellular calcium release, and chemotaxis toward CCL19.","method":"CRAM expression analysis, calcium mobilization assay, MAP-kinase phosphorylation assay, chemotaxis assay in CLL patient cells","journal":"Molecular cancer","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — multiple functional assays in primary patient cells, receptor competition mechanism, single lab","pmids":["21092185"],"is_preprint":false},{"year":2006,"finding":"Activation of NF-κB-induced astrocyte gliosis upregulates astrocyte-derived CCL19, which retains CCR7-expressing lymphoma cells in brain parenchyma to promote CNS lymphoma; genetic deletion of CCL19 or CCR7 from lymphoma cells abolishes CNS lymphoma development.","method":"CCL19-knockout mice, CCR7-knockout lymphoma cells, two-photon microscopy of lymphoma cell brain entry and retention, NF-κB induction model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — two genetic knockouts (host CCL19 and tumor CCR7) with live two-photon imaging of cell retention, clear mechanistic pathway","pmids":["31526758"],"is_preprint":false},{"year":2023,"finding":"CCL19+ dendritic cells in triple-negative breast cancer exhibit migratory and immunomodulatory phenotypes; in vivo deletion of CCL19 (Ccl19 gene ablation) reduces CCR7+CD8+ T cells and impairs tumor elimination in response to anti-PD-1, establishing that DC-derived CCL19 is mechanistically required for effective anti-tumor immune responses.","method":"Ccl19 gene ablation in vivo, single-cell RNA sequencing, anti-PD-1 treatment with tumor growth readout, flow cytometry","journal":"Med","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic deletion with immune and tumor growth readouts, combined with single-cell profiling, multiple orthogonal methods","pmids":["37201522"],"is_preprint":false},{"year":2024,"finding":"CCL19-secreting fibroblasts facilitate lymphocyte trafficking to tertiary lymphoid structures (TLS) in colorectal cancer liver metastasis; CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice, establishing a causal role for fibroblast-derived CCL19 in TLS formation.","method":"Single-cell RNA sequencing, Stereo-seq spatial transcriptomics, CCL19 treatment in mouse model, CCL19+ fibroblast identification","journal":"Cancer cell","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo CCL19 treatment with TLS neogenesis readout plus spatial transcriptomics, single lab","pmids":["39137726"],"is_preprint":false},{"year":2015,"finding":"CCL19-CCR7 signaling protects from diet-induced obesity and insulin resistance: CCR7-/- mice fed high-fat diet are protected from obesity, fatty liver, dyslipidemia, and adipose tissue inflammation; CCL19 attracts activated dendritic cells to adipose tissue, and DC markers were absent in adipose tissue of CCR7-/- mice.","method":"CCR7-/- mice on high-fat diet, metabolic phenotyping, adipose tissue gene expression, flow cytometry for DC markers","journal":"Obesity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic knockout model with metabolic phenotyping and cellular mechanism, single lab","pmids":["26097021"],"is_preprint":false},{"year":2006,"finding":"Chemokines CCL19 and CCL21 constitutively expressed in secondary lymphoid organs promote activation-induced cell death (AICD) of antigen-responding CD4+ T cells; plt/plt mice (lacking CCL19/CCL21) show failure of CD4+ T cell clonal contraction; CCL19/CCL21 enhances AICD in vitro partly through upregulating Fas ligand.","method":"plt/plt genetic model, in vivo T cell response tracking, in vitro AICD assay with anti-CD3/CD28, FasL expression measurement","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic model with in vivo and in vitro mechanistic validation, FasL pathway identified, multiple readouts","pmids":["16973962"],"is_preprint":false},{"year":2005,"finding":"Nitric oxide (NO) via the cGMP/cGK pathway regulates DC migration toward CCL19: LPS-upregulated cGK phosphorylates VASP (a focal adhesion regulator), inhibiting DC migration; long-term NO treatment inhibits cGK-dependent VASP phosphorylation, releasing this brake and permitting CCL19-directed migration. Migration toward CCL19 requires cGK inhibition, unlike migration toward CXCL12.","method":"cGK activity assay, VASP phosphorylation by Western blot, NO donor treatment, pharmacological cGK inhibitors, DC migration assay","journal":"Blood","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — biochemical pathway dissection with pharmacological and molecular readouts, CCL19-specific migration assay; single lab","pmids":["16249377"],"is_preprint":false},{"year":2004,"finding":"A CCL19 N-terminal truncation mutant, CCL19(8-83), specifically antagonizes CCL19-induced chemotaxis and calcium mobilization without affecting CCL21 responses; treatment with this antagonist in vivo inhibits generation of cytotoxic T lymphocytes toward allogeneic DCs, demonstrating that CCL19 (distinct from CCL21) plays a role in immune priming.","method":"Calcium mobilization assay, Transwell chemotaxis assay, in vivo allogeneic CTL generation assay with CCL19(8-83) antagonist treatment","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — specific mutant antagonist with in vitro and in vivo validation, two orthogonal readouts; single lab","pmids":["15231820"],"is_preprint":false},{"year":2023,"finding":"CCL19 directly induces STAT5 phosphorylation in naive CD4+ T cells and upregulates genes associated with TH2 and IL-2 signaling pathways; Ccl19-deficient mice show reduced TH2 differentiation and allergic airway inflammation, placing CCL19 as a direct inducer of TH2 responses independent of DC migration.","method":"Ccl19-deficient mice (allergic asthma model), naive CD4+ T cell co-culture with Ccl19-/- DCs or fibroblastic reticular cells, STAT5 phosphorylation (flow cytometry), RNA-sequencing, recombinant CCL19 addition to T cell cultures","journal":"The Journal of allergy and clinical immunology","confidence":"High","confidence_rationale":"Tier 2 / Strong — genetic knockout with multiple orthogonal mechanistic assays (co-culture, direct T cell stimulation, STAT5 signaling, RNA-seq), in vivo and in vitro validation","pmids":["37956733"],"is_preprint":false},{"year":2010,"finding":"CCL19 signaling in SCCHN cells activates PI3K, which activates Cdc42 GTPase at the leading edge; CCL19-induced Cdc42 membrane localization and GTPase activity are abolished by CCR7 or PI3K inhibition; Cdc42 knockdown reduces Rac activation, actin polymerization, and CCL19-induced invasion and migration, placing Cdc42 downstream of CCR7/PI3K in the invasion pathway.","method":"GTPase pull-down assay (Cdc42 activity), immunofluorescence (actin/Cdc42 localization), CCR7/PI3K inhibition, Cdc42 siRNA knockdown, Transwell invasion/migration assay","journal":"Oncology reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — GTPase activity assay, genetic knockdown, pharmacological pathway inhibition; multiple orthogonal readouts; single lab","pmids":["21165582"],"is_preprint":false}],"current_model":"CCL19 is a homeostatic CC chemokine that signals primarily through CCR7 (and is scavenged by atypical receptors ACKR4/CCX-CKR, CRAM/CCRL2) to orchestrate directional migration and functional maturation of T cells and dendritic cells: CCL19 binding to CCR7 activates G-protein-coupled pathways (PI3K/Akt, PLC/Ca2+, Rho/Rac/Cdc42, ERK/JNK, NF-κB) and recruits β-arrestin 3 to drive CCR7 internalization—a response mechanistically distinct from CCL21, which does not trigger CCR7 internalization or require arrestin; receptor internalization also acts as a self-generated chemokine sink that shapes extracellular CCL19 gradients to sustain collective DC migration; CCL19 expressed by T-zone stromal cells and DCs is transcytosed across HEV endothelium to enable lymphocyte arrest and homing, promotes full DC maturation and Th1/Th2 polarization (including direct STAT5-mediated TH2 induction), induces activation-induced cell death of antigen-responding T cells via Fas ligand upregulation, controls T cell lymph node egress through a CCR7→ERK5→KLF2→EDG-1 axis, and its local scavenging by ACKR4 on stromal cells establishes directional gradients critical for APC trafficking from inflamed skin."},"narrative":{"mechanistic_narrative":"CCL19 is a homeostatic CC chemokine that orchestrates the directional migration, arrest, and functional maturation of T cells and dendritic cells within secondary lymphoid organs [PMID:11070085, PMID:15845453]. It is expressed by T-zone stromal cells and CD8+ dendritic cells [PMID:11070085], and perivascular CCL19 is transcytosed to the luminal surface of high endothelial venules to drive CCR7-mediated lymphocyte arrest and lymph node homing [PMID:11342595]. Through its principal receptor CCR7, CCL19 engages G-protein-coupled cascades—PI3K/Akt, PLC/Ca2+, ERK/p38/NF-κB, and the Rho-family GTPases Rac and Cdc42—the latter driving rapid dendritic extension in mature DCs [PMID:14592837, PMID:12200351, PMID:27459960]. A defining feature distinguishing CCL19 from the co-ligand CCL21 is that CCL19 alone triggers β-arrestin-3-dependent CCR7 internalization and desensitization, a bias encoded by the chemokine core domain and CCR7 extracellular loop 2 [PMID:18802075, PMID:31572374]; this internalization additionally creates a self-generated chemokine sink that shapes extracellular gradients to sustain collective DC migration [PMID:37656776]. CCL19 also promotes DC maturation and Th1 programming [PMID:15845453], directly induces STAT5-dependent TH2 differentiation in naive CD4+ T cells [PMID:37956733], drives T-cell lymph node egress via a CCR7→ERK5→KLF2→EDG-1 axis [PMID:22334704], and enforces clonal contraction through Fas-ligand-mediated activation-induced cell death [PMID:16973962]. Extracellular CCL19 abundance is controlled by the atypical scavenging receptors ACKR4/CCX-CKR and CCRL2/CRAM, which bind CCL19 with high affinity but, rather than signaling, internalize and degrade it to establish directional gradients for APC trafficking [PMID:10706668, PMID:16791897, PMID:20002784, PMID:26976955]. Although CCL19 is sufficient to mediate these activities, it is dispensable in vivo when CCL21 is intact, and only combined CCL19/CCL21 loss reproduces the CCR7-null phenotype [PMID:20039103]. Beyond lymphoid homeostasis, CCL19-CCR7 signaling contributes to tumor immunity and pathology, including DC-dependent anti-tumor responses and tertiary lymphoid structure formation [PMID:37201522, PMID:39137726], CNS lymphoma retention [PMID:31526758], and CCR7-driven invasion programs in carcinoma cells [PMID:23649655, PMID:21165582].","teleology":[{"year":2000,"claim":"Establishing where CCL19 is produced was prerequisite to understanding its role in lymphoid architecture; the finding localized it to T-zone stromal cells and CD8+ DCs co-expressing CCL21.","evidence":"Double in situ hybridization and bone marrow reconstitution in wild-type and plt/plt mice","pmids":["11070085"],"confidence":"High","gaps":["Does not separate the functional contributions of stromal- versus DC-derived CCL19","Co-expression with CCL21 leaves individual ligand roles unresolved"]},{"year":2000,"claim":"Receptor profiling answered which receptors bind CCL19, identifying CCX-CKR (ACKR4) as a high-affinity binder in addition to CCR7 and laying the groundwork for the scavenger-receptor concept.","evidence":"Stalk-immobilized chemokine adhesion and radiolabeled competition binding across >80 chemokines","pmids":["10706668"],"confidence":"High","gaps":["Binding alone did not establish whether CCX-CKR signals or scavenges","In vivo relevance not addressed"]},{"year":2000,"claim":"Placing CCL19 within a defined trafficking pathway, this work showed DC egress from skin epidermis requires CCL19 downstream of leukotriene signaling.","evidence":"In vitro chemotaxis with LTC4/LTD4 rescue, MRP1-/- mice, and in vivo CCL19 antagonism","pmids":["11114332"],"confidence":"High","gaps":["Did not distinguish CCL19 from CCL21 contributions in vivo","Receptor coupling not directly tested"]},{"year":2001,"claim":"Demonstrating how luminal CCL19 reaches circulating lymphocytes explained CCR7-mediated arrest at HEVs, showing transcytosis enables homing and that injected CCL19 rescues trafficking in plt/plt mice.","evidence":"ISH, IHC vesicle localization, and footpad-injection lymph node trafficking rescue in plt/plt mice","pmids":["11342595"],"confidence":"High","gaps":["Molecular machinery of transcytosis not identified","Functional redundancy with CCL21 in this assay"]},{"year":2001,"claim":"A core functional distinction between the two CCR7 ligands emerged: CCL19, but not CCL21, induces CCR7 internalization and desensitization.","evidence":"Flow cytometry surface receptor and functional re-stimulation assays on T cells","pmids":["11745346"],"confidence":"Medium","gaps":["Mechanism of internalization not yet defined","Single-lab observation"]},{"year":2002,"claim":"Linking CCL19 to lymphoid neogenesis, ectopic CCL19 induced organized infiltrates and lymphotoxin expression, connecting the chemokine to tissue organization.","evidence":"CCL19 transgenic mice, histopathology, LTα1β2 assays, LTβR-Fc antagonism","pmids":["12077273"],"confidence":"High","gaps":["Ectopic expression may not reflect physiologic levels","Receptor mediating LT induction not confirmed"]},{"year":2002,"claim":"Identifying the cytoskeletal effectors of CCL19, this work showed rapid dendritic extension in mature DCs via Rac/Cdc42, distinct from CCL21.","evidence":"DC morphology assay with toxin B and Y-27632 inhibitors, time-course imaging","pmids":["12200351"],"confidence":"Medium","gaps":["GTPase identity inferred pharmacologically, not genetically","Functional consequence of dendritic extension untested"]},{"year":2003,"claim":"Resolving a signaling co-requirement, PGE2 was shown to license CCR7 coupling to PI3K/Akt and Ca2+ for DC migration.","evidence":"Phosphorylation and calcium assays with PLC/PI3K inhibitors in DC migration","pmids":["14592837"],"confidence":"High","gaps":["Molecular basis of PGE2-CCR7 coupling unresolved","In vivo requirement not tested"]},{"year":2004,"claim":"An expanded cellular source was defined—activated neutrophils produce biologically active CCL19 that recruits DCs and triggers lymphocyte adhesion.","evidence":"LPS/TNFα-stimulated neutrophil culture, chemotaxis and integrin adhesion assays with neutralizing antibody","pmids":["11449350"],"confidence":"Medium","gaps":["In vivo relevance of neutrophil-derived CCL19 not shown","Single-lab finding"]},{"year":2004,"claim":"A specific CCL19 antagonist established a non-redundant role for CCL19 in immune priming distinct from CCL21.","evidence":"CCL19(8-83) truncation antagonist in calcium, chemotaxis, and in vivo allogeneic CTL assays","pmids":["15231820"],"confidence":"Medium","gaps":["Antagonist specificity may incompletely separate ligands in vivo","Single-lab finding"]},{"year":2005,"claim":"Connecting CCL19 to DC functional programming, the chemokine was shown to mature migratory CCR7-high DCs and program them for Th1 induction.","evidence":"Expression cloning, DC-T cell coculture, maturation marker flow cytometry, cytokine ELISA, plt/plt model","pmids":["15845453"],"confidence":"High","gaps":["Does not isolate CCL19 from CCL21 contributions in plt/plt mice","Th1-skewing mechanism not molecularly defined"]},{"year":2005,"claim":"A regulatory brake on CCL19-directed migration was identified in the NO/cGMP/cGK→VASP pathway.","evidence":"cGK activity and VASP phosphorylation assays, NO donor and cGK inhibitor DC migration","pmids":["16249377"],"confidence":"Medium","gaps":["Physiologic source of NO regulating DCs unclear","CCL19-specificity mechanism not fully explained"]},{"year":2006,"claim":"Resolving how CCL19 levels are controlled, ACKR4/CCX-CKR was shown to sustain scavenging and degrade internalized CCL19 via a caveolin-1 route distinct from CCR7.","evidence":"Transfected HEK293 cells, radiolabeled CCL19 internalization/degradation, caveolin and β-arrestin manipulation","pmids":["16791897"],"confidence":"High","gaps":["In vivo gradient-shaping role not yet established here","Reconstituted cell system"]},{"year":2006,"claim":"A self-limiting function of CCL19 in adaptive immunity emerged: it promotes activation-induced cell death of responding CD4+ T cells via Fas ligand to enforce clonal contraction.","evidence":"plt/plt mice T cell response tracking and in vitro AICD/FasL assays","pmids":["16973962"],"confidence":"High","gaps":["CCL19 versus CCL21 contributions not separated","Receptor and signaling route to FasL not mapped"]},{"year":2006,"claim":"Extending CCL19-CCR7 beyond lymphoid tissue, the pathway was shown to drive proinflammatory and procoagulant programs in vascular cells relevant to atherosclerosis.","evidence":"In vitro macrophage/fibroblast stimulation with MMP/tissue factor/VEGF ELISA","pmids":["17170367"],"confidence":"Medium","gaps":["Causal role in plaque destabilization not demonstrated in vivo","Single-lab finding"]},{"year":2008,"claim":"The molecular basis of ligand-biased CCR7 internalization was pinned to β-arrestin 3, required for CCL19 but not CCL21 responses.","evidence":"siRNA and arrestin-null MEF reconstitution with internalization and migration assays","pmids":["18802075"],"confidence":"High","gaps":["Did not define the ligand structural determinant of bias","Downstream functional consequences of bias in vivo untested"]},{"year":2009,"claim":"A second atypical scavenger was added: CRAM/CCRL2 on B cells binds CCL19 with CCR7-like affinity but internalizes rather than signals.","evidence":"Radiolabeled binding, negative calcium/migration assays, internalization in CRAM-transfected cells","pmids":["20002784"],"confidence":"Medium","gaps":["In vivo scavenging role not established","Single-lab finding"]},{"year":2010,"claim":"Genetic dissection clarified ligand redundancy: CCL21 is sufficient and CCL19 dispensable in vivo, with only combined loss phenocopying CCR7 deficiency.","evidence":"CCL19-deficient mice with DC migration, maturation, priming readouts versus double knockout","pmids":["20039103"],"confidence":"High","gaps":["Does not exclude CCL19-specific roles under inflammatory or other contexts","Mechanism of compensation by CCL21 unclear"]},{"year":2010,"claim":"Quantitative gradient sensing showed DCs preferentially navigate toward CCL21 over CCL19, refining how the two ligands guide migration.","evidence":"Microfluidic 3D gradient device with quantitative DC tracking","pmids":["21422278"],"confidence":"Medium","gaps":["In vivo gradient configurations not directly tested","Single-lab finding"]},{"year":2010,"claim":"Signaling branch analysis in CLL cells separated migration (PI3K/Rho-ROCK) from survival (ERK/JNK/PI3K) outputs of CCR7.","evidence":"Dominant-negative/constitutively active mutants, inhibitors, Rho pull-down, chemotaxis/apoptosis assays","pmids":["20488224"],"confidence":"Medium","gaps":["Ligand-specificity (CCL19 vs CCL21) not separated","Disease-cell context may not generalize"]},{"year":2010,"claim":"Competitive scavenging by CRAM was shown to blunt CCR7 signaling in CLL B cells, supporting CRAM as a tuner of CCL19 availability.","evidence":"CRAM expression analysis with calcium, MAPK, and chemotaxis assays in patient cells","pmids":["21092185"],"confidence":"Medium","gaps":["Causality in disease progression not established","Single-lab finding"]},{"year":2010,"claim":"PI3K/Akt was placed downstream of CCL19/CCR7 in T cell effector cytokine output.","evidence":"Akt phosphorylation, PI3K inhibition, IFN-γ ELISA, CCR7 knockdown in HBV-responsive T cells","pmids":["34218330"],"confidence":"Low","gaps":["Single pathway readout with pharmacological inhibition only","Not independently confirmed"]},{"year":2012,"claim":"The egress program was defined: CCL19-CCR7 drives an ERK5→KLF2→EDG-1 axis controlling T cell lymph node exit.","evidence":"ERK5/KLF2/EDG-1 signaling assays and conditional ERK5-knockout T cells with migration readouts","pmids":["22334704"],"confidence":"High","gaps":["CCL19 versus CCL21 contributions to egress not isolated","In vivo egress kinetics not directly measured here"]},{"year":2013,"claim":"A tumor-invasion mechanism was mapped: CCL19/CCR7 induces heparanase via Sp1 to promote lung adenocarcinoma invasion.","evidence":"ChIP for Sp1-heparanase promoter binding, pathway inhibition, Transwell invasion","pmids":["23649655"],"confidence":"Medium","gaps":["In vivo metastatic relevance not tested","Single cell line, single lab"]},{"year":2014,"claim":"CCR7 was confirmed as the mediator of CCL19-driven monocyte adhesion and migration to endothelium in an atherogenic context.","evidence":"Monocyte-HUVEC adhesion/migration with CCR7-neutralizing antibody","pmids":["24990231"],"confidence":"Medium","gaps":["In vivo atherogenesis contribution not shown","Single-lab finding"]},{"year":2015,"claim":"Structural mapping revealed CCL19 adopts the chemokine fold and that CCR7 and PSGL-1 N-termini compete at overlapping sites, suggesting co-presentation enhances recruitment.","evidence":"NMR solution structure, chemical shift mapping, competitive binding","pmids":["26115234"],"confidence":"High","gaps":["Functional impact of PSGL-1 co-presentation not tested in vivo","Single-lab finding"]},{"year":2015,"claim":"A metabolic role emerged: CCL19-CCR7 recruitment of DCs to adipose tissue contributes to diet-induced obesity and insulin resistance.","evidence":"CCR7-/- mice on high-fat diet with metabolic phenotyping and DC marker analysis","pmids":["26097021"],"confidence":"Medium","gaps":["CCL19-specific (vs CCL21) contribution not isolated","Single-lab finding"]},{"year":2016,"claim":"In vivo gradient shaping by scavenging was established: ACKR4 on skin stroma scavenges CCL19 specifically to enable APC egress, with Ccl19 deletion rescuing the Ackr4-null phenotype.","evidence":"Ackr4-/- mice, Ccl19-/- genetic rescue, flow cytometry of skin APC populations","pmids":["26976955"],"confidence":"High","gaps":["Quantitative gradient measurements in tissue not provided","Mechanism limited to inflammatory conditions"]},{"year":2016,"claim":"A non-canonical role for CCL19 in HIV biology was reported, linking CCR7 signaling to NF-κB-dependent integration and JNK/Pin1-mediated integrase stabilization in resting T cells.","evidence":"Pathway phosphorylation/inhibitor assays, NF-κB-mutant virus, Alu-LTR qPCR, Pin1 Co-IP","pmids":["27459960"],"confidence":"Medium","gaps":["Pin1-integrase interaction from single Co-IP","Physiologic relevance to HIV reservoirs not established"]},{"year":2019,"claim":"The structural determinants of CCR7 signaling bias were defined: the chemokine core domain (not N-terminus) and CCR7 ECL2/K130 encode differential G-protein versus β-arrestin coupling.","evidence":"BRET signaling assays, chimeric CCL19/CCL21 ligands, CCR7 mutagenesis, migration assays, modeling","pmids":["31572374"],"confidence":"High","gaps":["No experimental receptor-ligand complex structure","In vivo consequences of bias determinants not tested"]},{"year":2023,"claim":"The internalization-driven sink concept matured into a gradient-self-organization mechanism: CCR7-CCL19 uptake by DCs shapes gradients to enable collective long-range migration.","evidence":"Live-cell imaging, gradient assays, and mathematical modeling of DC migration","pmids":["37656776"],"confidence":"High","gaps":["In vivo validation of self-generated gradients limited","Quantitative parameters tissue-specific"]},{"year":2023,"claim":"A DC-migration-independent mechanism was uncovered: CCL19 directly induces STAT5 phosphorylation in naive CD4+ T cells to drive TH2 differentiation and allergic inflammation.","evidence":"Ccl19-deficient asthma model, T cell co-culture, STAT5 flow cytometry, RNA-seq, recombinant CCL19","pmids":["37956733"],"confidence":"High","gaps":["Receptor mediating direct STAT5 induction not defined here","How a chemokine activates STAT5 mechanistically unresolved"]},{"year":2023,"claim":"CCL19 was shown to be mechanistically required for effective anti-tumor immunity, supporting CCR7+CD8+ T cell responses and anti-PD-1 efficacy in breast cancer.","evidence":"Ccl19 gene ablation, scRNA-seq, anti-PD-1 with tumor growth and flow readouts","pmids":["37201522"],"confidence":"High","gaps":["Cellular source of relevant CCL19 not fully isolated","Receptor route in this context inferred"]},{"year":2024,"claim":"Fibroblast-derived CCL19 was assigned a causal role in tertiary lymphoid structure formation, promoting lymphocyte trafficking and anti-tumor protection in liver metastasis.","evidence":"scRNA-seq, Stereo-seq spatial transcriptomics, CCL19 treatment in mice","pmids":["39137726"],"confidence":"Medium","gaps":["Mechanism of TLS neogenesis induction not molecularly resolved","Single-lab finding"]},{"year":null,"claim":"How CCL19 activates a direct STAT5/JAK-type transcriptional program in T cells—and how this reconciles with its canonical CCR7 GPCR signaling—remains to be mechanistically defined.","evidence":"","pmids":[],"confidence":"Low","gaps":["Receptor and proximal kinase coupling CCL19 to STAT5 unidentified","Relationship between scavenger receptors and direct T cell signaling unexplored","No receptor-bound structure of CCL19 to explain ligand bias"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0048018","term_label":"receptor ligand activity","supporting_discovery_ids":[1,16,33]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[6,11,15,18]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[10,12,17]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,9,29]},{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[1]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,1,7,31,34]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[6,11,15,19]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[4,14,20]}],"complexes":[],"partners":["CCR7","ACKR4","CCRL2","PSGL-1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99731","full_name":"C-C motif chemokine 19","aliases":["Beta-chemokine exodus-3","CK beta-11","Epstein-Barr virus-induced molecule 1 ligand chemokine","EBI1 ligand chemokine","ELC","Macrophage inflammatory protein 3 beta","MIP-3-beta","Small-inducible cytokine A19"],"length_aa":98,"mass_kda":11.0,"function":"May play a role not only in inflammatory and immunological responses but also in normal lymphocyte recirculation and homing. May play an important role in trafficking of T-cells in thymus, and T-cell and B-cell migration to secondary lymphoid organs. Binds to chemokine receptor CCR7. Recombinant CCL19 shows potent chemotactic activity for T-cells and B-cells but not for granulocytes and monocytes. Binds to atypical chemokine receptor ACKR4 and mediates the recruitment of beta-arrestin (ARRB1/2) to ACKR4","subcellular_location":"Secreted","url":"https://www.uniprot.org/uniprotkb/Q99731/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/CCL19","classification":"Not Classified","n_dependent_lines":4,"n_total_lines":1208,"dependency_fraction":0.0033112582781456954},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/CCL19","total_profiled":1310},"omim":[{"mim_id":"608379","title":"CHEMOKINE, CC MOTIF, RECEPTOR-LIKE PROTEIN 2; CCRL2","url":"https://www.omim.org/entry/608379"},{"mim_id":"607003","title":"THYMIC STROMAL LYMPHOPOIETIN; TSLP","url":"https://www.omim.org/entry/607003"},{"mim_id":"606065","title":"ATYPICAL CHEMOKINE RECEPTOR 4; ACKR4","url":"https://www.omim.org/entry/606065"},{"mim_id":"605149","title":"CHEMOKINE, CXC MOTIF, LIGAND 13; CXCL13","url":"https://www.omim.org/entry/605149"},{"mim_id":"603030","title":"TOLL-LIKE RECEPTOR 4; TLR4","url":"https://www.omim.org/entry/603030"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"lymphoid tissue","ntpm":591.4}],"url":"https://www.proteinatlas.org/search/CCL19"},"hgnc":{"alias_symbol":["ELC","MIP-3b","exodus-3","CKb11"],"prev_symbol":["SCYA19"]},"alphafold":{"accession":"Q99731","domains":[{"cath_id":"2.40.50.40","chopping":"28-98","consensus_level":"medium","plddt":93.3169,"start":28,"end":98}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99731","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99731-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99731-F1-predicted_aligned_error_v6.png","plddt_mean":83.19},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CCL19","jax_strain_url":"https://www.jax.org/strain/search?query=CCL19"},"sequence":{"accession":"Q99731","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99731.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99731/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99731"}},"corpus_meta":[{"pmid":"29505028","id":"PMC_29505028","title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor.","date":"2018","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/29505028","citation_count":647,"is_preprint":false},{"pmid":"12077273","id":"PMC_12077273","title":"Differing activities of homeostatic chemokines CCL19, CCL21, and CXCL12 in lymphocyte and dendritic cell recruitment and lymphoid neogenesis.","date":"2002","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/12077273","citation_count":464,"is_preprint":false},{"pmid":"11070085","id":"PMC_11070085","title":"Coexpression of the chemokines ELC and SLC by T zone stromal cells and deletion of the ELC gene in the plt/plt mouse.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11070085","citation_count":459,"is_preprint":false},{"pmid":"11114332","id":"PMC_11114332","title":"The leukotriene C(4) transporter MRP1 regulates CCL19 (MIP-3beta, ELC)-dependent mobilization of dendritic cells to lymph nodes.","date":"2000","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/11114332","citation_count":354,"is_preprint":false},{"pmid":"11342595","id":"PMC_11342595","title":"The CCR7 ligand elc (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11342595","citation_count":275,"is_preprint":false},{"pmid":"34325726","id":"PMC_34325726","title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin.","date":"2021","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34325726","citation_count":253,"is_preprint":false},{"pmid":"23587803","id":"PMC_23587803","title":"A myriad of functions and complex regulation of the CCR7/CCL19/CCL21 chemokine axis in the adaptive immune system.","date":"2013","source":"Cytokine & growth factor reviews","url":"https://pubmed.ncbi.nlm.nih.gov/23587803","citation_count":242,"is_preprint":false},{"pmid":"15845453","id":"PMC_15845453","title":"CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells.","date":"2005","source":"Immunity","url":"https://pubmed.ncbi.nlm.nih.gov/15845453","citation_count":215,"is_preprint":false},{"pmid":"14592837","id":"PMC_14592837","title":"CCL19/CCL21-triggered signal transduction and migration of dendritic cells requires prostaglandin E2.","date":"2003","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/14592837","citation_count":194,"is_preprint":false},{"pmid":"21389340","id":"PMC_21389340","title":"Seminal fluid regulates accumulation of FOXP3+ regulatory T cells in the preimplantation mouse uterus through expanding the FOXP3+ cell pool and CCL19-mediated recruitment.","date":"2011","source":"Biology of reproduction","url":"https://pubmed.ncbi.nlm.nih.gov/21389340","citation_count":182,"is_preprint":false},{"pmid":"21422278","id":"PMC_21422278","title":"Dendritic cell chemotaxis in 3D under defined chemokine gradients reveals differential response to ligands CCL21 and CCL19.","date":"2011","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/21422278","citation_count":165,"is_preprint":false},{"pmid":"31632965","id":"PMC_31632965","title":"CCL19 and CCR7 Expression, Signaling Pathways, and Adjuvant Functions in Viral Infection and Prevention.","date":"2019","source":"Frontiers in cell and developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/31632965","citation_count":162,"is_preprint":false},{"pmid":"26729814","id":"PMC_26729814","title":"Common and biased signaling pathways of the chemokine receptor CCR7 elicited by its ligands CCL19 and CCL21 in leukocytes.","date":"2016","source":"Journal of leukocyte biology","url":"https://pubmed.ncbi.nlm.nih.gov/26729814","citation_count":159,"is_preprint":false},{"pmid":"12209625","id":"PMC_12209625","title":"Functional expression of the lymphoid chemokines CCL19 (ELC) and CCL 21 (SLC) at the blood-brain barrier suggests their involvement in G-protein-dependent lymphocyte recruitment into the central nervous system during experimental autoimmune encephalomyelitis.","date":"2002","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/12209625","citation_count":155,"is_preprint":false},{"pmid":"10706668","id":"PMC_10706668","title":"Cutting edge: identification of a novel chemokine receptor that binds dendritic cell- and T cell-active chemokines including ELC, SLC, and TECK.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10706668","citation_count":154,"is_preprint":false},{"pmid":"11148224","id":"PMC_11148224","title":"Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses.","date":"2001","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/11148224","citation_count":150,"is_preprint":false},{"pmid":"11449350","id":"PMC_11449350","title":"Neutrophils produce biologically active macrophage inflammatory protein-3alpha (MIP-3alpha)/CCL20 and MIP-3beta/CCL19.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11449350","citation_count":136,"is_preprint":false},{"pmid":"17170367","id":"PMC_17170367","title":"Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization.","date":"2006","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/17170367","citation_count":128,"is_preprint":false},{"pmid":"39137726","id":"PMC_39137726","title":"CCL19-producing fibroblasts promote tertiary lymphoid structure formation enhancing anti-tumor IgG response in colorectal cancer liver metastasis.","date":"2024","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/39137726","citation_count":126,"is_preprint":false},{"pmid":"30250188","id":"PMC_30250188","title":"CCL19 suppresses angiogenesis through promoting miR-206 and inhibiting Met/ERK/Elk-1/HIF-1α/VEGF-A pathway in colorectal cancer.","date":"2018","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/30250188","citation_count":125,"is_preprint":false},{"pmid":"21225692","id":"PMC_21225692","title":"Characterization of CCL19 and CCL21 in rheumatoid arthritis.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21225692","citation_count":125,"is_preprint":false},{"pmid":"16791897","id":"PMC_16791897","title":"The chemokine receptor CCX-CKR mediates effective scavenging of CCL19 in vitro.","date":"2006","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16791897","citation_count":123,"is_preprint":false},{"pmid":"12580544","id":"PMC_12580544","title":"Lymphoid chemokines CCL19 and CCL21 are expressed in the central nervous system during experimental autoimmune encephalomyelitis: implications for the maintenance of chronic neuroinflammation.","date":"2003","source":"Brain pathology (Zurich, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/12580544","citation_count":123,"is_preprint":false},{"pmid":"11745346","id":"PMC_11745346","title":"The T cell chemokine receptor CCR7 is internalized on stimulation with ELC, but not with SLC.","date":"2001","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/11745346","citation_count":105,"is_preprint":false},{"pmid":"20498301","id":"PMC_20498301","title":"PGE(2) transiently enhances DC expression of CCR7 but inhibits the ability of DCs to produce CCL19 and attract naive T cells.","date":"2010","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/20498301","citation_count":103,"is_preprint":false},{"pmid":"10754294","id":"PMC_10754294","title":"The CC chemokine CK beta-11/MIP-3 beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells.","date":"2000","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/10754294","citation_count":102,"is_preprint":false},{"pmid":"10027395","id":"PMC_10027395","title":"Expression and cellular localization of the CC chemokines PARC and ELC in human atherosclerotic plaques.","date":"1999","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/10027395","citation_count":93,"is_preprint":false},{"pmid":"9701028","id":"PMC_9701028","title":"EBI1-ligand chemokine (ELC) attracts a broad spectrum of lymphocytes: activated T cells strongly up-regulate CCR7 and efficiently migrate toward ELC.","date":"1998","source":"International immunology","url":"https://pubmed.ncbi.nlm.nih.gov/9701028","citation_count":86,"is_preprint":false},{"pmid":"20201039","id":"PMC_20201039","title":"CCL21 is sufficient to mediate DC migration, maturation and function in the absence of CCL19.","date":"2010","source":"European journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20201039","citation_count":79,"is_preprint":false},{"pmid":"18802075","id":"PMC_18802075","title":"Arrestin 3 mediates endocytosis of CCR7 following ligation of CCL19 but not CCL21.","date":"2008","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/18802075","citation_count":78,"is_preprint":false},{"pmid":"12200351","id":"PMC_12200351","title":"CCL19 induces rapid dendritic extension of murine dendritic cells.","date":"2002","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/12200351","citation_count":77,"is_preprint":false},{"pmid":"15331393","id":"PMC_15331393","title":"Increased expression of CCL18, CCL19, and CCL17 by dendritic cells from patients with rheumatoid arthritis, and regulation by Fc gamma receptors.","date":"2004","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/15331393","citation_count":76,"is_preprint":false},{"pmid":"19454681","id":"PMC_19454681","title":"CCR7-CCL19/CCL21-regulated dendritic cells are responsible for effectiveness of sublingual vaccination.","date":"2009","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/19454681","citation_count":75,"is_preprint":false},{"pmid":"33767695","id":"PMC_33767695","title":"The BCMA-Targeted Fourth-Generation CAR-T Cells Secreting IL-7 and CCL19 for Therapy of Refractory/Recurrent Multiple Myeloma.","date":"2021","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/33767695","citation_count":73,"is_preprint":false},{"pmid":"10222066","id":"PMC_10222066","title":"CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKbeta-11/MIP-3beta/ELC, are chemoattractants for CD56(+)CD16(-) NK cells and late stage lymphoid progenitors.","date":"1999","source":"Cellular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/10222066","citation_count":72,"is_preprint":false},{"pmid":"29391257","id":"PMC_29391257","title":"CCL19-producing fibroblastic stromal cells restrain lung carcinoma growth by promoting local antitumor T-cell responses.","date":"2018","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29391257","citation_count":72,"is_preprint":false},{"pmid":"14662845","id":"PMC_14662845","title":"EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.","date":"2003","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/14662845","citation_count":70,"is_preprint":false},{"pmid":"26976955","id":"PMC_26976955","title":"ACKR4 on Stromal Cells Scavenges CCL19 To Enable CCR7-Dependent Trafficking of APCs from Inflamed Skin to Lymph Nodes.","date":"2016","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26976955","citation_count":61,"is_preprint":false},{"pmid":"23873879","id":"PMC_23873879","title":"Global chemokine expression in systemic sclerosis (SSc): CCL19 expression correlates with vascular inflammation in SSc skin.","date":"2013","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/23873879","citation_count":55,"is_preprint":false},{"pmid":"23308044","id":"PMC_23308044","title":"Expression of CCL19 from oncolytic vaccinia enhances immunotherapeutic potential while maintaining oncolytic activity.","date":"2012","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/23308044","citation_count":55,"is_preprint":false},{"pmid":"20002784","id":"PMC_20002784","title":"CCL19 is a specific ligand of the constitutively recycling atypical human chemokine receptor CRAM-B.","date":"2009","source":"Immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20002784","citation_count":55,"is_preprint":false},{"pmid":"14871974","id":"PMC_14871974","title":"CCL19 and CXCL12 trigger in vitro chemotaxis of human mantle cell lymphoma B cells.","date":"2004","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/14871974","citation_count":54,"is_preprint":false},{"pmid":"33559069","id":"PMC_33559069","title":"Enhanced anti-tumor efficacy of IL-7/CCL19-producing human CAR-T cells in orthotopic and patient-derived xenograft tumor models.","date":"2021","source":"Cancer immunology, immunotherapy : CII","url":"https://pubmed.ncbi.nlm.nih.gov/33559069","citation_count":51,"is_preprint":false},{"pmid":"37853185","id":"PMC_37853185","title":"GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.","date":"2023","source":"Cell biology and toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/37853185","citation_count":48,"is_preprint":false},{"pmid":"35020885","id":"PMC_35020885","title":"Does CCL19 act as a double-edged sword in cancer development?","date":"2022","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/35020885","citation_count":48,"is_preprint":false},{"pmid":"18757429","id":"PMC_18757429","title":"CXCL13 is highly produced by Sézary cells and enhances their migratory ability via a synergistic mechanism involving CCL19 and CCL21 chemokines.","date":"2008","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/18757429","citation_count":48,"is_preprint":false},{"pmid":"12474232","id":"PMC_12474232","title":"Differential expression of CCL19 by DC-Lamp+ mature dendritic cells in human lymph node versus chronically inflamed skin.","date":"2003","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/12474232","citation_count":48,"is_preprint":false},{"pmid":"36479116","id":"PMC_36479116","title":"Development of Nectin4/FAP-targeted CAR-T cells secreting IL-7, CCL19, and IL-12 for malignant solid tumors.","date":"2022","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36479116","citation_count":47,"is_preprint":false},{"pmid":"30940644","id":"PMC_30940644","title":"Accumulation of Circulating CCR7+ Natural Killer Cells Marks Melanoma Evolution and Reveals a CCL19-Dependent Metastatic Pathway.","date":"2019","source":"Cancer immunology research","url":"https://pubmed.ncbi.nlm.nih.gov/30940644","citation_count":44,"is_preprint":false},{"pmid":"17947663","id":"PMC_17947663","title":"Regulatory role of lymphoid chemokine CCL19 and CCL21 in the control of allergic rhinitis.","date":"2007","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/17947663","citation_count":44,"is_preprint":false},{"pmid":"37656776","id":"PMC_37656776","title":"CCR7 acts as both a sensor and a sink for CCL19 to coordinate collective leukocyte migration.","date":"2023","source":"Science immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37656776","citation_count":43,"is_preprint":false},{"pmid":"16598185","id":"PMC_16598185","title":"CCL19 reduces tumour burden in a model of advanced lung cancer.","date":"2006","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16598185","citation_count":43,"is_preprint":false},{"pmid":"23740460","id":"PMC_23740460","title":"CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.","date":"2013","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/23740460","citation_count":42,"is_preprint":false},{"pmid":"16675330","id":"PMC_16675330","title":"Role of CCL21 and CCL19 in allergic inflammation in the ovalbumin-specific murine asthmatic model.","date":"2006","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/16675330","citation_count":41,"is_preprint":false},{"pmid":"30339734","id":"PMC_30339734","title":"Adipose tissue expression of CCL19 chemokine is positively associated with insulin resistance.","date":"2018","source":"Diabetes/metabolism research and reviews","url":"https://pubmed.ncbi.nlm.nih.gov/30339734","citation_count":40,"is_preprint":false},{"pmid":"24990231","id":"PMC_24990231","title":"Contribution of homeostatic chemokines CCL19 and CCL21 and their receptor CCR7 to coronary artery disease.","date":"2014","source":"Arteriosclerosis, thrombosis, and vascular biology","url":"https://pubmed.ncbi.nlm.nih.gov/24990231","citation_count":40,"is_preprint":false},{"pmid":"23649655","id":"PMC_23649655","title":"CCL19/CCR7 upregulates heparanase via specificity protein-1 (Sp1) to promote invasion of cell in lung cancer.","date":"2013","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/23649655","citation_count":40,"is_preprint":false},{"pmid":"21383953","id":"PMC_21383953","title":"Gamma-ray irradiation impairs dendritic cell migration to CCL19 by down-regulation of CCR7 and induction of cell apoptosis.","date":"2011","source":"International journal of biological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/21383953","citation_count":40,"is_preprint":false},{"pmid":"23858028","id":"PMC_23858028","title":"CCL19 and CCL28 augment mucosal and systemic immune responses to HIV-1 gp140 by mobilizing responsive immunocytes into secondary lymph nodes and mucosal tissue.","date":"2013","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/23858028","citation_count":39,"is_preprint":false},{"pmid":"28859865","id":"PMC_28859865","title":"Ischemic stroke damages the intestinal mucosa and induces alteration of the intestinal lymphocytes and CCL19 mRNA in rats.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/28859865","citation_count":38,"is_preprint":false},{"pmid":"37201522","id":"PMC_37201522","title":"CCL19+ dendritic cells potentiate clinical benefit of anti-PD-(L)1 immunotherapy in triple-negative breast cancer.","date":"2023","source":"Med (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/37201522","citation_count":37,"is_preprint":false},{"pmid":"16899521","id":"PMC_16899521","title":"CCL19-IgG prevents allograft rejection by impairment of immune cell trafficking.","date":"2006","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/16899521","citation_count":37,"is_preprint":false},{"pmid":"16249377","id":"PMC_16249377","title":"Nitric oxide and cGMP protein kinase (cGK) regulate dendritic-cell migration toward the lymph-node-directing chemokine CCL19.","date":"2005","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16249377","citation_count":37,"is_preprint":false},{"pmid":"26239696","id":"PMC_26239696","title":"Loss of RUNX3 expression promotes cancer-associated bone destruction by regulating CCL5, CCL19 and CXCL11 in non-small cell lung cancer.","date":"2015","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/26239696","citation_count":37,"is_preprint":false},{"pmid":"26097021","id":"PMC_26097021","title":"Protection from diet-induced obesity and insulin resistance in mice lacking CCL19-CCR7 signaling.","date":"2015","source":"Obesity (Silver Spring, Md.)","url":"https://pubmed.ncbi.nlm.nih.gov/26097021","citation_count":37,"is_preprint":false},{"pmid":"25636509","id":"PMC_25636509","title":"Crk-like adapter protein regulates CCL19/CCR7-mediated epithelial-to-mesenchymal transition via ERK signaling pathway in epithelial ovarian carcinomas.","date":"2015","source":"Medical oncology (Northwood, London, England)","url":"https://pubmed.ncbi.nlm.nih.gov/25636509","citation_count":36,"is_preprint":false},{"pmid":"20488224","id":"PMC_20488224","title":"Analysis of migratory and prosurvival pathways induced by the homeostatic chemokines CCL19 and CCL21 in B-cell chronic lymphocytic leukemia.","date":"2010","source":"Experimental hematology","url":"https://pubmed.ncbi.nlm.nih.gov/20488224","citation_count":36,"is_preprint":false},{"pmid":"31526758","id":"PMC_31526758","title":"Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention.","date":"2019","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/31526758","citation_count":35,"is_preprint":false},{"pmid":"21092185","id":"PMC_21092185","title":"Role of the atypical chemoattractant receptor CRAM in regulating CCL19 induced CCR7 responses in B-cell chronic lymphocytic leukemia.","date":"2010","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/21092185","citation_count":35,"is_preprint":false},{"pmid":"35400595","id":"PMC_35400595","title":"CCR7 expression in CD19 chimeric antigen receptor-engineered natural killer cells improves migration toward CCL19-expressing lymphoma cells and increases tumor control in mice with human lymphoma.","date":"2022","source":"Cytotherapy","url":"https://pubmed.ncbi.nlm.nih.gov/35400595","citation_count":34,"is_preprint":false},{"pmid":"38191529","id":"PMC_38191529","title":"Safety and feasibility of anti-CD19 CAR T cells expressing inducible IL-7 and CCL19 in patients with relapsed or refractory large B-cell lymphoma.","date":"2024","source":"Cell discovery","url":"https://pubmed.ncbi.nlm.nih.gov/38191529","citation_count":33,"is_preprint":false},{"pmid":"29088748","id":"PMC_29088748","title":"Increased CCL19 expression is associated with progression in cervical cancer.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29088748","citation_count":33,"is_preprint":false},{"pmid":"26115234","id":"PMC_26115234","title":"Solution Structure of CCL19 and Identification of Overlapping CCR7 and PSGL-1 Binding Sites.","date":"2015","source":"Biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/26115234","citation_count":33,"is_preprint":false},{"pmid":"31494219","id":"PMC_31494219","title":"The effects of CCL3, CCL4, CCL19 and CCL21 as molecular adjuvants on the immune response to VAA DNA vaccine in flounder (Paralichthys olivaceus).","date":"2019","source":"Developmental and comparative immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31494219","citation_count":33,"is_preprint":false},{"pmid":"19664149","id":"PMC_19664149","title":"Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication.","date":"2009","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/19664149","citation_count":33,"is_preprint":false},{"pmid":"12626344","id":"PMC_12626344","title":"Expression of macrophage inflammatory protein-3 beta/CCL19 in pulmonary sarcoidosis.","date":"2003","source":"American journal of respiratory and critical care medicine","url":"https://pubmed.ncbi.nlm.nih.gov/12626344","citation_count":32,"is_preprint":false},{"pmid":"26504105","id":"PMC_26504105","title":"Differential ligand-signaling network of CCL19/CCL21-CCR7 system.","date":"2015","source":"Database : the journal of biological databases and curation","url":"https://pubmed.ncbi.nlm.nih.gov/26504105","citation_count":32,"is_preprint":false},{"pmid":"24915301","id":"PMC_24915301","title":"Inhibition of chemokine (C-C motif) receptor 7 sialylation suppresses CCL19-stimulated proliferation, invasion and anti-anoikis.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24915301","citation_count":32,"is_preprint":false},{"pmid":"27459960","id":"PMC_27459960","title":"HIV integration and the establishment of latency in CCL19-treated resting CD4(+) T cells require activation of NF-κB.","date":"2016","source":"Retrovirology","url":"https://pubmed.ncbi.nlm.nih.gov/27459960","citation_count":31,"is_preprint":false},{"pmid":"28275068","id":"PMC_28275068","title":"CCR7-CCL19/CCL21 Axis is Essential for Effective Arteriogenesis in a Murine Model of Hindlimb Ischemia.","date":"2017","source":"Journal of the American Heart Association","url":"https://pubmed.ncbi.nlm.nih.gov/28275068","citation_count":31,"is_preprint":false},{"pmid":"17384577","id":"PMC_17384577","title":"CCL19 (ELC) as an adjuvant for DNA vaccination: induction of a TH1-type T-cell response and enhancement of antitumor immunity.","date":"2007","source":"Cancer gene therapy","url":"https://pubmed.ncbi.nlm.nih.gov/17384577","citation_count":30,"is_preprint":false},{"pmid":"15231820","id":"PMC_15231820","title":"Inhibition of generation of cytotoxic T lymphocyte activity by a CCL19/macrophage inflammatory protein (MIP)-3beta antagonist.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/15231820","citation_count":30,"is_preprint":false},{"pmid":"32564199","id":"PMC_32564199","title":"CCL19 suppresses gastric cancer cell proliferation, migration, and invasion through the CCL19/CCR7/AIM2 pathway.","date":"2020","source":"Human cell","url":"https://pubmed.ncbi.nlm.nih.gov/32564199","citation_count":29,"is_preprint":false},{"pmid":"34218330","id":"PMC_34218330","title":"CCL19 enhances CD8+ T-cell responses and accelerates HBV clearance.","date":"2021","source":"Journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/34218330","citation_count":28,"is_preprint":false},{"pmid":"25473269","id":"PMC_25473269","title":"CCL19 and CCL21 modulate the inflammatory milieu in atherosclerotic lesions.","date":"2014","source":"Drug design, development and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/25473269","citation_count":28,"is_preprint":false},{"pmid":"16500130","id":"PMC_16500130","title":"Dendritic cells express CCR7 and migrate in response to CCL19 (MIP-3beta) after exposure to Helicobacter pylori.","date":"2006","source":"Microbes and infection","url":"https://pubmed.ncbi.nlm.nih.gov/16500130","citation_count":28,"is_preprint":false},{"pmid":"21165582","id":"PMC_21165582","title":"CCL19-induced chemokine receptor 7 activates the phosphoinositide-3 kinase-mediated invasive pathway through Cdc42 in metastatic squamous cell carcinoma of the head and neck.","date":"2010","source":"Oncology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21165582","citation_count":28,"is_preprint":false},{"pmid":"37956733","id":"PMC_37956733","title":"Chemokine CCL19 promotes type 2 T-cell differentiation and allergic airway inflammation.","date":"2023","source":"The Journal of allergy and clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/37956733","citation_count":27,"is_preprint":false},{"pmid":"31068931","id":"PMC_31068931","title":"Elevated CCL19/CCR7 Expression During the Disease Process of Primary Sjögren's Syndrome.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31068931","citation_count":27,"is_preprint":false},{"pmid":"28062181","id":"PMC_28062181","title":"Epicatechin downregulates adipose tissue CCL19 expression and thereby ameliorates diet-induced obesity and insulin resistance.","date":"2016","source":"Nutrition, metabolism, and cardiovascular diseases : NMCD","url":"https://pubmed.ncbi.nlm.nih.gov/28062181","citation_count":27,"is_preprint":false},{"pmid":"28856757","id":"PMC_28856757","title":"CCL19/CCR7 contributes to the pathogenesis of endometriosis via PI3K/Akt pathway by regulating the proliferation and invasion of ESCs.","date":"2017","source":"American journal of reproductive immunology (New York, N.Y. : 1989)","url":"https://pubmed.ncbi.nlm.nih.gov/28856757","citation_count":27,"is_preprint":false},{"pmid":"22976543","id":"PMC_22976543","title":"The expression of chemokines CCL19, CCL21 and their receptor CCR7 in oral squamous cell carcinoma and its relevance to cervical lymph node metastasis.","date":"2012","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/22976543","citation_count":27,"is_preprint":false},{"pmid":"28807994","id":"PMC_28807994","title":"A Novel Computational Model Predicts Key Regulators of Chemokine Gradient Formation in Lymph Nodes and Site-Specific Roles for CCL19 and ACKR4.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/28807994","citation_count":27,"is_preprint":false},{"pmid":"30518137","id":"PMC_30518137","title":"Fluorescently Tagged CCL19 and CCL21 to Monitor CCR7 and ACKR4 Functions.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30518137","citation_count":26,"is_preprint":false},{"pmid":"22334704","id":"PMC_22334704","title":"CCR7/CCL19 controls expression of EDG-1 in T cells.","date":"2012","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/22334704","citation_count":26,"is_preprint":false},{"pmid":"29061765","id":"PMC_29061765","title":"CK12a, a CCL19-like Chemokine That Orchestrates both Nasal and Systemic Antiviral Immune Responses in Rainbow Trout.","date":"2017","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/29061765","citation_count":26,"is_preprint":false},{"pmid":"25086360","id":"PMC_25086360","title":"Matrix metalloproteinase-9 is up-regulated by CCL19/CCR7 interaction via PI3K/Akt pathway and is involved in CCL19-driven BMSCs migration.","date":"2014","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/25086360","citation_count":25,"is_preprint":false},{"pmid":"16973962","id":"PMC_16973962","title":"Chemokines CCL19 and CCL21 promote activation-induced cell death of antigen-responding T cells.","date":"2006","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/16973962","citation_count":25,"is_preprint":false},{"pmid":"27031839","id":"PMC_27031839","title":"Graft Site Microenvironment Determines Dendritic Cell Trafficking Through the CCR7-CCL19/21 Axis.","date":"2016","source":"Investigative ophthalmology & visual science","url":"https://pubmed.ncbi.nlm.nih.gov/27031839","citation_count":25,"is_preprint":false},{"pmid":"31572374","id":"PMC_31572374","title":"Biased Signaling of CCL21 and CCL19 Does Not Rely on N-Terminal Differences, but Markedly on the Chemokine Core Domains and Extracellular Loop 2 of CCR7.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/31572374","citation_count":25,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":53147,"output_tokens":9204,"usd":0.148751,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":19417,"output_tokens":8384,"usd":0.153342,"stage2_stop_reason":"end_turn"},"total_usd":0.302093,"stage1_batch_id":"msgbatch_01ACAxJQabDsht39JXeWG22d","stage2_batch_id":"msgbatch_01QEU22A9U5sbPTgsMzTmvSf","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL19 (ELC) is expressed by T zone stromal cells (which co-express SLC/CCL21) and by CD8+ dendritic cells in secondary lymphoid organs; this co-expression was established by double in situ hybridization and bone marrow reconstitution experiments in wild-type mice, with both genes deleted in plt/plt mice.\",\n      \"method\": \"Double in situ hybridization, bone marrow reconstitution, genetic deletion (plt/plt mouse)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal localization by two orthogonal methods (double ISH + BM reconstitution) replicated across the plt/plt genetic model\",\n      \"pmids\": [\"11070085\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Perivascular CCL19 is transcytosed to the luminal surface of high endothelial venules (HEVs) and enables CCR7-mediated T cell arrest and homing to lymph nodes; injected CCL19 in plt/plt mice restored T cell trafficking to draining lymph nodes as efficiently as CCL21.\",\n      \"method\": \"In situ hybridization, immunohistochemistry (cytoplasmic vesicle localization), footpad injection with lymph node trafficking assay in plt/plt mice\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (ISH, IHC, in vivo rescue in genetic model) in a single study with clear functional readout\",\n      \"pmids\": [\"11342595\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"CCL19 induces rapid, concentration-dependent internalization of CCR7 on T lymphocytes, markedly reducing subsequent responsiveness to re-stimulation; in contrast, CCL21 does not induce CCR7 internalization, establishing a fundamental functional difference between the two CCR7 ligands.\",\n      \"method\": \"Flow cytometry receptor surface expression, functional re-stimulation assays\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct receptor trafficking assay with two orthogonal readouts (surface expression + functional desensitization), single lab\",\n      \"pmids\": [\"11745346\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CCL19 acts as a functional ligand for CCX-CKR (later ACKR4/CCX-CKR), in addition to CCR7; CCX-CKR binds CCL19 with high affinity (IC50 <15 nM) and also binds CCL21 and TECK, identified by stalk-immobilized chemokine adhesion assay and radiolabeled competition binding.\",\n      \"method\": \"Stalkokine adhesion assay, radiolabeled ligand binding and competition with >80 chemokines\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — in vitro binding reconstitution with radiolabeled ligand and competition across >80 chemokines; comprehensive profiling\",\n      \"pmids\": [\"10706668\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"DC migration from skin epidermis to lymph nodes requires CCL19: in vitro cysteinyl leukotrienes (LTC4, LTD4) promoted optimal chemotaxis to CCL19 (but not other chemokines), and in vivo antagonism of CCL19 prevented DC egress from the epidermis, placing CCL19 downstream of MRP1-transported LTC4 in a defined DC trafficking pathway.\",\n      \"method\": \"In vitro chemotaxis assay, MRP1-/- mice, exogenous LTC4/LTD4 rescue, in vivo CCL19 antagonism\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout combined with pharmacological rescue and in vivo antagonism, multiple orthogonal approaches in a single study\",\n      \"pmids\": [\"11114332\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Ectopic expression of CCL19 in pancreatic islets induces infiltrates composed of lymphocytes and DCs containing high endothelial venules; CCL19 (like CCL21 but not CXCL12) induces LTα1β2 expression on naive CD4 T cells, suggesting CCL19 drives lymphoid neogenesis partly through induction of lymphotoxin.\",\n      \"method\": \"CCL19 transgenic mouse model, histopathology, LTα1β2 expression assays, LTβR-Fc antagonist treatment\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transgenic in vivo model with pharmacological antagonist rescue, multiple cell and molecular readouts, comparative ligand analysis\",\n      \"pmids\": [\"12077273\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"CCL19/CCL21-triggered CCR7 signal transduction and DC migration require prostaglandin E2 (PGE2) for coupling: PGE2 enables CCR7 to activate PI3K-mediated Akt phosphorylation and intracellular Ca2+ mobilization; migration depends on PLC and intracellular Ca2+ flux but not PI3K.\",\n      \"method\": \"Phosphorylation assays (PI3K/Akt), intracellular calcium mobilization, pharmacological inhibitors (PLC, PI3K), DC migration assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro biochemical assays with multiple pathway inhibitors, two orthogonal signaling readouts (Ca2+ and Akt), single lab\",\n      \"pmids\": [\"14592837\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"CCL19 (signaling through CCR7) induces maturation of activated/migratory DCs (upregulation of costimulatory molecules and proinflammatory cytokines) and programs them for Th1 induction; only CCR7-high migrating DCs (not resting lymph-node-resident DCs) respond to CCL19 with cytokine production; plt/plt DCs (lacking CCL19 and CCL21) display only partially mature phenotype in vivo.\",\n      \"method\": \"Alphaviral expression cloning, DC-T cell coculture proliferation assay, flow cytometry (maturation markers), cytokine ELISA, plt/plt genetic model\",\n      \"journal\": \"Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (expression screen, coculture, genetic model), replicated in vitro and in vivo\",\n      \"pmids\": [\"15845453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"CCL19 rapidly induces marked dendritic extension (within 30 min) in mature but not immature DCs via Rac and/or Cdc42 GTPases (not Rho/ROCK), as shown by complete blockade with Clostridium difficile toxin B but not Y-27632; CCL21 fails to induce rapid dendritic extension.\",\n      \"method\": \"Murine DC morphology assay, pharmacological inhibitors (toxin B, Y-27632), time-course imaging\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — pharmacological dissection with two inhibitors, clear differential CCL19 vs CCL21 response, single lab\",\n      \"pmids\": [\"12200351\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"CCL19 is produced by neutrophils when stimulated with LPS or TNFα; neutrophil-derived CCL19 is biologically active, inducing chemotaxis of DCs and rapid integrin-dependent adhesion of CCR7-expressing lymphocytes to ICAM-1, as demonstrated by neutralizing antibody blockade.\",\n      \"method\": \"Neutrophil culture with LPS/TNFα, chemotaxis assay, integrin adhesion assay, neutralizing antibody blockade\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional chemotaxis and adhesion assays with neutralizing antibody confirmation, single lab, two orthogonal readouts\",\n      \"pmids\": [\"11449350\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCX-CKR (ACKR4) mediates progressive scavenging and degradation of CCL19: after CCL19 uptake, CCR7 rapidly desensitizes and cannot sustain further scavenging, but CCX-CKR maintains enhanced sequestration activity and degrades internalized CCL19. CCX-CKR uses a caveolin-1-dependent (not clathrin/β-arrestin-dependent) endocytic route distinct from CCR7.\",\n      \"method\": \"Transfected HEK293 cells, radiolabeled CCL19 internalization and degradation assay, siRNA/caveolin-1 overexpression, β-arrestin knockdown\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted receptor system with radiolabeled ligand, multiple mechanistic inhibitors, and mechanistic distinction between two receptors in one study\",\n      \"pmids\": [\"16791897\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"Arrestin 3 (β-arrestin 3) specifically mediates CCR7 internalization following CCL19 binding but is not required for CCL21-induced internalization; CCR7/CCL19 internalization and migration to CCL19 both require arrestin 3, whereas CCR7/CCL21 internalization and migration to CCL21 are arrestin-independent.\",\n      \"method\": \"siRNA knockdown of arrestin 2 and 3, arrestin 2-/-/arrestin 3-/- MEFs reconstituted with arrestin-GFP constructs, flow cytometry, immunofluorescence microscopy, Transwell migration assay\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — genetic and biochemical reconstitution (null MEFs + rescue), multiple orthogonal assays (receptor internalization + migration), two-ligand comparison\",\n      \"pmids\": [\"18802075\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CCL19 is a specific ligand for CRAM (CCRL2), an atypical chemokine receptor on B lymphocytes; CRAM binds CCL19 with affinity similar to CCR7 but does not induce calcium mobilization or chemotaxis; instead, CRAM constitutively recycles via clathrin-coated pits and internalizes CCL19, functioning as a scavenger receptor.\",\n      \"method\": \"Radioactive binding assay, calcium mobilization assay, migration assay, internalization assay with anti-CRAM antibodies, CRAM-expressing transfected cells\",\n      \"journal\": \"Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding with radiolabeled ligand, negative functional assays, internalization assay; single lab but multiple methods\",\n      \"pmids\": [\"20002784\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL21 is sufficient for DC migration, maturation, and T cell priming in vivo; CCL19 alone is not required: CCL19-deficient mice with intact CCL21 show normal DC frequencies, localization, skin DC migration, maturation, and T cell priming, whereas combined CCL19/CCL21 deficiency reproduces the CCR7-/- phenotype.\",\n      \"method\": \"CCL19-deficient mice (genetic knockout), flow cytometry, skin DC migration assay, T cell priming assay, lymph node histology\",\n      \"journal\": \"European journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — clean genetic knockout with multiple orthogonal readouts (migration, maturation, priming) and comparative analysis with double-knockout\",\n      \"pmids\": [\"20039103\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL21-stimulated DC chemotaxis in 3D gradients is more potent than CCL19 at high gradient concentrations; at small gradients (≤60 nM/mm) DCs respond similarly to both ligands. When exposed to equal/opposing gradients, DCs preferentially migrate toward CCL21 over CCL19, even when matrix binding of CCL21 is prevented.\",\n      \"method\": \"Microfluidic 3D gradient device with defined chemokine gradients, quantitative DC chemotaxis tracking\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — quantitative 3D migration assay, systematic gradient comparison, single lab\",\n      \"pmids\": [\"21422278\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"CCR7/CCL19 signaling upregulates ERK5 and subsequently the transcription factor KLF2 and EDG-1 (S1P receptor 1) expression in T cells; ERK5-deficient T cells (Lck-Cre/ERK5-flox) fail to upregulate EDG-1 in response to CCL19, and show impaired migration toward EDG-1 ligands, defining a CCL19→CCR7→ERK5→KLF2→EDG-1 axis controlling T cell lymph node egress.\",\n      \"method\": \"Signaling assays (ERK5 phosphorylation, KLF2 and EDG-1 expression), conditional knockout mice (ERK5flox/flox/Lck-Cre), Transwell migration assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — conditional genetic knockout rescue experiments combined with molecular pathway analysis across two cell types (cell line and primary T cells)\",\n      \"pmids\": [\"22334704\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"The solution structure of CCL19 contains a canonical chemokine fold; NMR chemical shift mapping shows that the N-termini of CCR7 and PSGL-1 have overlapping and competitive binding sites on CCL19, suggesting PSGL-1 enhances T cell recruitment by co-presentation of CCL19.\",\n      \"method\": \"NMR solution structure determination, NMR chemical shift mapping, competitive binding assay\",\n      \"journal\": \"Biochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — NMR structure with functional binding site mapping and competitive inhibition, single lab\",\n      \"pmids\": [\"26115234\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ACKR4 on stromal cells (keratinocytes and dermal lymphatic endothelial cells) scavenges dermal CCL19 during cutaneous inflammation to enable APC egress from skin; Ackr4-deficient mice show impaired Langerhans cell egress and DC accumulation in lymph nodes, and this phenotype is fully rescued by genetic deletion of Ccl19, establishing that ACKR4 functions specifically by scavenging CCL19 (not CCL21) under inflammatory conditions.\",\n      \"method\": \"Ackr4-/- mice, Ccl19-/- genetic rescue (double knockout), flow cytometry of skin APC populations, ACKR4-dependent chemokine scavenging in situ\",\n      \"journal\": \"Journal of immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic double-knockout rescue experiment with multiple flow cytometric readouts, demonstrates specificity for CCL19 over CCL21\",\n      \"pmids\": [\"26976955\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"CCL19 treatment of resting CD4+ T cells activates NF-κB, PI3K/Akt, ERK, and p38 signaling pathways; HIV integration in CCL19-treated resting T cells requires NF-κB signaling (HIV LTR NF-κB mutants show 40-fold reduced integration), and CCL19 stabilizes HIV integrase via a JNK-dependent Pin1 interaction, reducing proteasomal degradation.\",\n      \"method\": \"Phosphorylation assays (Akt, ERK, NF-κB, p38), pathway inhibitors (PI3K, MEK, JNK, NF-κB), HIV infection with NF-κB-site mutant virus, Alu-LTR/2-LTR qPCR, Pin1 co-immunoprecipitation\",\n      \"journal\": \"Retrovirology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple pharmacological inhibitors and mutant virus, Co-IP for Pin1 interaction, single lab\",\n      \"pmids\": [\"27459960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Biased signaling between CCL19 and CCL21 through CCR7 is determined by the chemokine core domains (not the N-termini): chimeric ligands with swapped N-termini retain original signaling properties, while swapping core domains transfers signaling bias. Extracellular loop 2 (ECL2) of CCR7 interacts differentially with the two ligands and is central to signaling bias; lysine K130 (TM3) selectively regulates G protein (but not β-arrestin-2) signaling.\",\n      \"method\": \"BRET-based signaling assays (G protein, β-arrestin recruitment), chimeric CCL19/CCL21 ligands, CCR7 mutagenesis screen, Transwell migration assay, in silico modeling\",\n      \"journal\": \"Frontiers in immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — structure-function mutagenesis with reconstituted BRET assays and chimeric ligands, multiple signaling pathways assessed; single lab\",\n      \"pmids\": [\"31572374\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCR7 acts as both a sensor and a sink for CCL19: upon CCL19 exposure, DCs internalize CCR7-CCL19 complexes as part of canonical GPCR desensitization, and this internalization acts as an effective chemokine sink that dynamically shapes CCL19 gradients. This self-generated gradient mechanism drives collective DC migration, enables long-range guidance, adapts to environmental geometry, and provides guidance cues for co-migrating cells.\",\n      \"method\": \"Live-cell imaging, mathematical modeling of chemokine gradients, experimental CCL19 gradient assays, DC migration tracking\",\n      \"journal\": \"Science immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — combination of quantitative experimental migration data and mechanistic mathematical modeling, multiple orthogonal readouts, novel dual-function mechanism demonstrated\",\n      \"pmids\": [\"37656776\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"CCL19 promotes proinflammatory cytokine production (including MMP and tissue factor) in macrophages and VEGF/angiopoietin-I in fibroblasts via CCR7; in atherosclerosis, CCL19 and CCL21 upregulate MMP and tissue factor in macrophages, potentially contributing to plaque destabilization.\",\n      \"method\": \"In vitro macrophage and fibroblast stimulation, ELISA for MMP/tissue factor/VEGF/Ang-I, CCR7-expressing cell lines\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional in vitro stimulation assays with protein readouts, single lab, multiple cell types\",\n      \"pmids\": [\"17170367\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"CCL19/CCR7 signaling promotes monocyte adhesion to endothelial cells via CCR7; CCR7-neutralizing antibody abolishes both CCL19- and CCL21-induced monocyte-to-HUVEC migration and CCL19-induced adhesion, placing CCR7 as the mediator of CCL19-driven atherogenic monocyte trafficking.\",\n      \"method\": \"Cell adhesion assay (monocyte to HUVEC), CCR7-neutralizing antibody blockade, cell migration assay\",\n      \"journal\": \"Arteriosclerosis, thrombosis, and vascular biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional cell adhesion/migration assay with receptor neutralization, single lab\",\n      \"pmids\": [\"24990231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CCL19/CCR7 upregulates heparanase expression in lung adenocarcinoma A549 cells via the transcription factor Sp1; Sp1 binds the heparanase promoter (confirmed by chromatin immunoprecipitation), and CCL19-induced invasion is dependent on this CCR7→Sp1→heparanase pathway.\",\n      \"method\": \"Western blot, RT-PCR, CCR7 blockade, Sp1 inhibition, chromatin immunoprecipitation, Transwell invasion assay\",\n      \"journal\": \"Tumour biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — ChIP for direct promoter binding, pathway inhibition at multiple nodes, invasion readout; single lab\",\n      \"pmids\": [\"23649655\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL19/CCL21-CCR7 signaling in CLL cells promotes migration via PI3K and Rho/ROCK pathways (but not MAPKs), while CCR7-mediated survival requires ERK, JNK, and PI3K; activation of Akt, RhoA/ROCK/MLC and MAPK were confirmed biochemically.\",\n      \"method\": \"Pharmacological inhibitors, dominant-negative and constitutively active PI3K/RhoA mutants, pull-down assay (Rho activation), immunoblotting, chemotaxis and apoptosis assays\",\n      \"journal\": \"Experimental hematology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic dominant-negative constructs plus pharmacological inhibitors, multiple biochemical and functional readouts; single lab\",\n      \"pmids\": [\"20488224\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL19-induced CCR7 signaling leads to increased phosphorylation of Akt in resting CD4+ T cells; PI3K inhibition partially suppresses IFN-γ secretion from HBV-responsive T cells stimulated with CCL19, placing PI3K downstream of CCL19/CCR7 in T cell activation.\",\n      \"method\": \"Phosphorylation assays (Akt), PI3K inhibitor (LY294002), IFN-γ ELISA, CCR7 knockdown\",\n      \"journal\": \"Journal of gastroenterology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — pharmacological inhibition with single pathway readout, single lab; full paper PMID 34218330 (2021 publication date actually)\",\n      \"pmids\": [\"34218330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CRAM (CCRL2) expressed at high levels on CLL B cells competitively reduces CCL19 availability for CCR7, blunting CCR7-dependent MAP-kinase phosphorylation, intracellular calcium release, and chemotaxis toward CCL19.\",\n      \"method\": \"CRAM expression analysis, calcium mobilization assay, MAP-kinase phosphorylation assay, chemotaxis assay in CLL patient cells\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — multiple functional assays in primary patient cells, receptor competition mechanism, single lab\",\n      \"pmids\": [\"21092185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Activation of NF-κB-induced astrocyte gliosis upregulates astrocyte-derived CCL19, which retains CCR7-expressing lymphoma cells in brain parenchyma to promote CNS lymphoma; genetic deletion of CCL19 or CCR7 from lymphoma cells abolishes CNS lymphoma development.\",\n      \"method\": \"CCL19-knockout mice, CCR7-knockout lymphoma cells, two-photon microscopy of lymphoma cell brain entry and retention, NF-κB induction model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — two genetic knockouts (host CCL19 and tumor CCR7) with live two-photon imaging of cell retention, clear mechanistic pathway\",\n      \"pmids\": [\"31526758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCL19+ dendritic cells in triple-negative breast cancer exhibit migratory and immunomodulatory phenotypes; in vivo deletion of CCL19 (Ccl19 gene ablation) reduces CCR7+CD8+ T cells and impairs tumor elimination in response to anti-PD-1, establishing that DC-derived CCL19 is mechanistically required for effective anti-tumor immune responses.\",\n      \"method\": \"Ccl19 gene ablation in vivo, single-cell RNA sequencing, anti-PD-1 treatment with tumor growth readout, flow cytometry\",\n      \"journal\": \"Med\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic deletion with immune and tumor growth readouts, combined with single-cell profiling, multiple orthogonal methods\",\n      \"pmids\": [\"37201522\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"CCL19-secreting fibroblasts facilitate lymphocyte trafficking to tertiary lymphoid structures (TLS) in colorectal cancer liver metastasis; CCL19 treatment promotes TLS neogenesis and prevents tumor growth in mice, establishing a causal role for fibroblast-derived CCL19 in TLS formation.\",\n      \"method\": \"Single-cell RNA sequencing, Stereo-seq spatial transcriptomics, CCL19 treatment in mouse model, CCL19+ fibroblast identification\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo CCL19 treatment with TLS neogenesis readout plus spatial transcriptomics, single lab\",\n      \"pmids\": [\"39137726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"CCL19-CCR7 signaling protects from diet-induced obesity and insulin resistance: CCR7-/- mice fed high-fat diet are protected from obesity, fatty liver, dyslipidemia, and adipose tissue inflammation; CCL19 attracts activated dendritic cells to adipose tissue, and DC markers were absent in adipose tissue of CCR7-/- mice.\",\n      \"method\": \"CCR7-/- mice on high-fat diet, metabolic phenotyping, adipose tissue gene expression, flow cytometry for DC markers\",\n      \"journal\": \"Obesity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic knockout model with metabolic phenotyping and cellular mechanism, single lab\",\n      \"pmids\": [\"26097021\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Chemokines CCL19 and CCL21 constitutively expressed in secondary lymphoid organs promote activation-induced cell death (AICD) of antigen-responding CD4+ T cells; plt/plt mice (lacking CCL19/CCL21) show failure of CD4+ T cell clonal contraction; CCL19/CCL21 enhances AICD in vitro partly through upregulating Fas ligand.\",\n      \"method\": \"plt/plt genetic model, in vivo T cell response tracking, in vitro AICD assay with anti-CD3/CD28, FasL expression measurement\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic model with in vivo and in vitro mechanistic validation, FasL pathway identified, multiple readouts\",\n      \"pmids\": [\"16973962\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Nitric oxide (NO) via the cGMP/cGK pathway regulates DC migration toward CCL19: LPS-upregulated cGK phosphorylates VASP (a focal adhesion regulator), inhibiting DC migration; long-term NO treatment inhibits cGK-dependent VASP phosphorylation, releasing this brake and permitting CCL19-directed migration. Migration toward CCL19 requires cGK inhibition, unlike migration toward CXCL12.\",\n      \"method\": \"cGK activity assay, VASP phosphorylation by Western blot, NO donor treatment, pharmacological cGK inhibitors, DC migration assay\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — biochemical pathway dissection with pharmacological and molecular readouts, CCL19-specific migration assay; single lab\",\n      \"pmids\": [\"16249377\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"A CCL19 N-terminal truncation mutant, CCL19(8-83), specifically antagonizes CCL19-induced chemotaxis and calcium mobilization without affecting CCL21 responses; treatment with this antagonist in vivo inhibits generation of cytotoxic T lymphocytes toward allogeneic DCs, demonstrating that CCL19 (distinct from CCL21) plays a role in immune priming.\",\n      \"method\": \"Calcium mobilization assay, Transwell chemotaxis assay, in vivo allogeneic CTL generation assay with CCL19(8-83) antagonist treatment\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — specific mutant antagonist with in vitro and in vivo validation, two orthogonal readouts; single lab\",\n      \"pmids\": [\"15231820\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"CCL19 directly induces STAT5 phosphorylation in naive CD4+ T cells and upregulates genes associated with TH2 and IL-2 signaling pathways; Ccl19-deficient mice show reduced TH2 differentiation and allergic airway inflammation, placing CCL19 as a direct inducer of TH2 responses independent of DC migration.\",\n      \"method\": \"Ccl19-deficient mice (allergic asthma model), naive CD4+ T cell co-culture with Ccl19-/- DCs or fibroblastic reticular cells, STAT5 phosphorylation (flow cytometry), RNA-sequencing, recombinant CCL19 addition to T cell cultures\",\n      \"journal\": \"The Journal of allergy and clinical immunology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — genetic knockout with multiple orthogonal mechanistic assays (co-culture, direct T cell stimulation, STAT5 signaling, RNA-seq), in vivo and in vitro validation\",\n      \"pmids\": [\"37956733\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"CCL19 signaling in SCCHN cells activates PI3K, which activates Cdc42 GTPase at the leading edge; CCL19-induced Cdc42 membrane localization and GTPase activity are abolished by CCR7 or PI3K inhibition; Cdc42 knockdown reduces Rac activation, actin polymerization, and CCL19-induced invasion and migration, placing Cdc42 downstream of CCR7/PI3K in the invasion pathway.\",\n      \"method\": \"GTPase pull-down assay (Cdc42 activity), immunofluorescence (actin/Cdc42 localization), CCR7/PI3K inhibition, Cdc42 siRNA knockdown, Transwell invasion/migration assay\",\n      \"journal\": \"Oncology reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — GTPase activity assay, genetic knockdown, pharmacological pathway inhibition; multiple orthogonal readouts; single lab\",\n      \"pmids\": [\"21165582\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CCL19 is a homeostatic CC chemokine that signals primarily through CCR7 (and is scavenged by atypical receptors ACKR4/CCX-CKR, CRAM/CCRL2) to orchestrate directional migration and functional maturation of T cells and dendritic cells: CCL19 binding to CCR7 activates G-protein-coupled pathways (PI3K/Akt, PLC/Ca2+, Rho/Rac/Cdc42, ERK/JNK, NF-κB) and recruits β-arrestin 3 to drive CCR7 internalization—a response mechanistically distinct from CCL21, which does not trigger CCR7 internalization or require arrestin; receptor internalization also acts as a self-generated chemokine sink that shapes extracellular CCL19 gradients to sustain collective DC migration; CCL19 expressed by T-zone stromal cells and DCs is transcytosed across HEV endothelium to enable lymphocyte arrest and homing, promotes full DC maturation and Th1/Th2 polarization (including direct STAT5-mediated TH2 induction), induces activation-induced cell death of antigen-responding T cells via Fas ligand upregulation, controls T cell lymph node egress through a CCR7→ERK5→KLF2→EDG-1 axis, and its local scavenging by ACKR4 on stromal cells establishes directional gradients critical for APC trafficking from inflamed skin.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"CCL19 is a homeostatic CC chemokine that orchestrates the directional migration, arrest, and functional maturation of T cells and dendritic cells within secondary lymphoid organs [#0, #7]. It is expressed by T-zone stromal cells and CD8+ dendritic cells [#0], and perivascular CCL19 is transcytosed to the luminal surface of high endothelial venules to drive CCR7-mediated lymphocyte arrest and lymph node homing [#1]. Through its principal receptor CCR7, CCL19 engages G-protein-coupled cascades—PI3K/Akt, PLC/Ca2+, ERK/p38/NF-\\u03baB, and the Rho-family GTPases Rac and Cdc42—the latter driving rapid dendritic extension in mature DCs [#6, #8, #18]. A defining feature distinguishing CCL19 from the co-ligand CCL21 is that CCL19 alone triggers \\u03b2-arrestin-3-dependent CCR7 internalization and desensitization, a bias encoded by the chemokine core domain and CCR7 extracellular loop 2 [#11, #19]; this internalization additionally creates a self-generated chemokine sink that shapes extracellular gradients to sustain collective DC migration [#20]. CCL19 also promotes DC maturation and Th1 programming [#7], directly induces STAT5-dependent TH2 differentiation in naive CD4+ T cells [#34], drives T-cell lymph node egress via a CCR7\\u2192ERK5\\u2192KLF2\\u2192EDG-1 axis [#15], and enforces clonal contraction through Fas-ligand-mediated activation-induced cell death [#31]. Extracellular CCL19 abundance is controlled by the atypical scavenging receptors ACKR4/CCX-CKR and CCRL2/CRAM, which bind CCL19 with high affinity but, rather than signaling, internalize and degrade it to establish directional gradients for APC trafficking [#3, #10, #12, #17]. Although CCL19 is sufficient to mediate these activities, it is dispensable in vivo when CCL21 is intact, and only combined CCL19/CCL21 loss reproduces the CCR7-null phenotype [#13]. Beyond lymphoid homeostasis, CCL19-CCR7 signaling contributes to tumor immunity and pathology, including DC-dependent anti-tumor responses and tertiary lymphoid structure formation [#28, #29], CNS lymphoma retention [#27], and CCR7-driven invasion programs in carcinoma cells [#23, #35].\",\n  \"teleology\": [\n    {\n      \"year\": 2000,\n      \"claim\": \"Establishing where CCL19 is produced was prerequisite to understanding its role in lymphoid architecture; the finding localized it to T-zone stromal cells and CD8+ DCs co-expressing CCL21.\",\n      \"evidence\": \"Double in situ hybridization and bone marrow reconstitution in wild-type and plt/plt mice\",\n      \"pmids\": [\"11070085\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not separate the functional contributions of stromal- versus DC-derived CCL19\", \"Co-expression with CCL21 leaves individual ligand roles unresolved\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Receptor profiling answered which receptors bind CCL19, identifying CCX-CKR (ACKR4) as a high-affinity binder in addition to CCR7 and laying the groundwork for the scavenger-receptor concept.\",\n      \"evidence\": \"Stalk-immobilized chemokine adhesion and radiolabeled competition binding across >80 chemokines\",\n      \"pmids\": [\"10706668\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding alone did not establish whether CCX-CKR signals or scavenges\", \"In vivo relevance not addressed\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Placing CCL19 within a defined trafficking pathway, this work showed DC egress from skin epidermis requires CCL19 downstream of leukotriene signaling.\",\n      \"evidence\": \"In vitro chemotaxis with LTC4/LTD4 rescue, MRP1-/- mice, and in vivo CCL19 antagonism\",\n      \"pmids\": [\"11114332\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not distinguish CCL19 from CCL21 contributions in vivo\", \"Receptor coupling not directly tested\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Demonstrating how luminal CCL19 reaches circulating lymphocytes explained CCR7-mediated arrest at HEVs, showing transcytosis enables homing and that injected CCL19 rescues trafficking in plt/plt mice.\",\n      \"evidence\": \"ISH, IHC vesicle localization, and footpad-injection lymph node trafficking rescue in plt/plt mice\",\n      \"pmids\": [\"11342595\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular machinery of transcytosis not identified\", \"Functional redundancy with CCL21 in this assay\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"A core functional distinction between the two CCR7 ligands emerged: CCL19, but not CCL21, induces CCR7 internalization and desensitization.\",\n      \"evidence\": \"Flow cytometry surface receptor and functional re-stimulation assays on T cells\",\n      \"pmids\": [\"11745346\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of internalization not yet defined\", \"Single-lab observation\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Linking CCL19 to lymphoid neogenesis, ectopic CCL19 induced organized infiltrates and lymphotoxin expression, connecting the chemokine to tissue organization.\",\n      \"evidence\": \"CCL19 transgenic mice, histopathology, LT\\u03b11\\u03b22 assays, LT\\u03b2R-Fc antagonism\",\n      \"pmids\": [\"12077273\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Ectopic expression may not reflect physiologic levels\", \"Receptor mediating LT induction not confirmed\"]\n    },\n    {\n      \"year\": 2002,\n      \"claim\": \"Identifying the cytoskeletal effectors of CCL19, this work showed rapid dendritic extension in mature DCs via Rac/Cdc42, distinct from CCL21.\",\n      \"evidence\": \"DC morphology assay with toxin B and Y-27632 inhibitors, time-course imaging\",\n      \"pmids\": [\"12200351\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"GTPase identity inferred pharmacologically, not genetically\", \"Functional consequence of dendritic extension untested\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Resolving a signaling co-requirement, PGE2 was shown to license CCR7 coupling to PI3K/Akt and Ca2+ for DC migration.\",\n      \"evidence\": \"Phosphorylation and calcium assays with PLC/PI3K inhibitors in DC migration\",\n      \"pmids\": [\"14592837\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis of PGE2-CCR7 coupling unresolved\", \"In vivo requirement not tested\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"An expanded cellular source was defined—activated neutrophils produce biologically active CCL19 that recruits DCs and triggers lymphocyte adhesion.\",\n      \"evidence\": \"LPS/TNF\\u03b1-stimulated neutrophil culture, chemotaxis and integrin adhesion assays with neutralizing antibody\",\n      \"pmids\": [\"11449350\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo relevance of neutrophil-derived CCL19 not shown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2004,\n      \"claim\": \"A specific CCL19 antagonist established a non-redundant role for CCL19 in immune priming distinct from CCL21.\",\n      \"evidence\": \"CCL19(8-83) truncation antagonist in calcium, chemotaxis, and in vivo allogeneic CTL assays\",\n      \"pmids\": [\"15231820\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Antagonist specificity may incompletely separate ligands in vivo\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Connecting CCL19 to DC functional programming, the chemokine was shown to mature migratory CCR7-high DCs and program them for Th1 induction.\",\n      \"evidence\": \"Expression cloning, DC-T cell coculture, maturation marker flow cytometry, cytokine ELISA, plt/plt model\",\n      \"pmids\": [\"15845453\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not isolate CCL19 from CCL21 contributions in plt/plt mice\", \"Th1-skewing mechanism not molecularly defined\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"A regulatory brake on CCL19-directed migration was identified in the NO/cGMP/cGK\\u2192VASP pathway.\",\n      \"evidence\": \"cGK activity and VASP phosphorylation assays, NO donor and cGK inhibitor DC migration\",\n      \"pmids\": [\"16249377\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Physiologic source of NO regulating DCs unclear\", \"CCL19-specificity mechanism not fully explained\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolving how CCL19 levels are controlled, ACKR4/CCX-CKR was shown to sustain scavenging and degrade internalized CCL19 via a caveolin-1 route distinct from CCR7.\",\n      \"evidence\": \"Transfected HEK293 cells, radiolabeled CCL19 internalization/degradation, caveolin and \\u03b2-arrestin manipulation\",\n      \"pmids\": [\"16791897\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo gradient-shaping role not yet established here\", \"Reconstituted cell system\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"A self-limiting function of CCL19 in adaptive immunity emerged: it promotes activation-induced cell death of responding CD4+ T cells via Fas ligand to enforce clonal contraction.\",\n      \"evidence\": \"plt/plt mice T cell response tracking and in vitro AICD/FasL assays\",\n      \"pmids\": [\"16973962\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCL19 versus CCL21 contributions not separated\", \"Receptor and signaling route to FasL not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Extending CCL19-CCR7 beyond lymphoid tissue, the pathway was shown to drive proinflammatory and procoagulant programs in vascular cells relevant to atherosclerosis.\",\n      \"evidence\": \"In vitro macrophage/fibroblast stimulation with MMP/tissue factor/VEGF ELISA\",\n      \"pmids\": [\"17170367\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causal role in plaque destabilization not demonstrated in vivo\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"The molecular basis of ligand-biased CCR7 internalization was pinned to \\u03b2-arrestin 3, required for CCL19 but not CCL21 responses.\",\n      \"evidence\": \"siRNA and arrestin-null MEF reconstitution with internalization and migration assays\",\n      \"pmids\": [\"18802075\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not define the ligand structural determinant of bias\", \"Downstream functional consequences of bias in vivo untested\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"A second atypical scavenger was added: CRAM/CCRL2 on B cells binds CCL19 with CCR7-like affinity but internalizes rather than signals.\",\n      \"evidence\": \"Radiolabeled binding, negative calcium/migration assays, internalization in CRAM-transfected cells\",\n      \"pmids\": [\"20002784\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo scavenging role not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Genetic dissection clarified ligand redundancy: CCL21 is sufficient and CCL19 dispensable in vivo, with only combined loss phenocopying CCR7 deficiency.\",\n      \"evidence\": \"CCL19-deficient mice with DC migration, maturation, priming readouts versus double knockout\",\n      \"pmids\": [\"20039103\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Does not exclude CCL19-specific roles under inflammatory or other contexts\", \"Mechanism of compensation by CCL21 unclear\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Quantitative gradient sensing showed DCs preferentially navigate toward CCL21 over CCL19, refining how the two ligands guide migration.\",\n      \"evidence\": \"Microfluidic 3D gradient device with quantitative DC tracking\",\n      \"pmids\": [\"21422278\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo gradient configurations not directly tested\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Signaling branch analysis in CLL cells separated migration (PI3K/Rho-ROCK) from survival (ERK/JNK/PI3K) outputs of CCR7.\",\n      \"evidence\": \"Dominant-negative/constitutively active mutants, inhibitors, Rho pull-down, chemotaxis/apoptosis assays\",\n      \"pmids\": [\"20488224\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Ligand-specificity (CCL19 vs CCL21) not separated\", \"Disease-cell context may not generalize\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Competitive scavenging by CRAM was shown to blunt CCR7 signaling in CLL B cells, supporting CRAM as a tuner of CCL19 availability.\",\n      \"evidence\": \"CRAM expression analysis with calcium, MAPK, and chemotaxis assays in patient cells\",\n      \"pmids\": [\"21092185\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Causality in disease progression not established\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"PI3K/Akt was placed downstream of CCL19/CCR7 in T cell effector cytokine output.\",\n      \"evidence\": \"Akt phosphorylation, PI3K inhibition, IFN-\\u03b3 ELISA, CCR7 knockdown in HBV-responsive T cells\",\n      \"pmids\": [\"34218330\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single pathway readout with pharmacological inhibition only\", \"Not independently confirmed\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"The egress program was defined: CCL19-CCR7 drives an ERK5\\u2192KLF2\\u2192EDG-1 axis controlling T cell lymph node exit.\",\n      \"evidence\": \"ERK5/KLF2/EDG-1 signaling assays and conditional ERK5-knockout T cells with migration readouts\",\n      \"pmids\": [\"22334704\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"CCL19 versus CCL21 contributions to egress not isolated\", \"In vivo egress kinetics not directly measured here\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"A tumor-invasion mechanism was mapped: CCL19/CCR7 induces heparanase via Sp1 to promote lung adenocarcinoma invasion.\",\n      \"evidence\": \"ChIP for Sp1-heparanase promoter binding, pathway inhibition, Transwell invasion\",\n      \"pmids\": [\"23649655\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo metastatic relevance not tested\", \"Single cell line, single lab\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"CCR7 was confirmed as the mediator of CCL19-driven monocyte adhesion and migration to endothelium in an atherogenic context.\",\n      \"evidence\": \"Monocyte-HUVEC adhesion/migration with CCR7-neutralizing antibody\",\n      \"pmids\": [\"24990231\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"In vivo atherogenesis contribution not shown\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Structural mapping revealed CCL19 adopts the chemokine fold and that CCR7 and PSGL-1 N-termini compete at overlapping sites, suggesting co-presentation enhances recruitment.\",\n      \"evidence\": \"NMR solution structure, chemical shift mapping, competitive binding\",\n      \"pmids\": [\"26115234\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional impact of PSGL-1 co-presentation not tested in vivo\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"A metabolic role emerged: CCL19-CCR7 recruitment of DCs to adipose tissue contributes to diet-induced obesity and insulin resistance.\",\n      \"evidence\": \"CCR7-/- mice on high-fat diet with metabolic phenotyping and DC marker analysis\",\n      \"pmids\": [\"26097021\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"CCL19-specific (vs CCL21) contribution not isolated\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"In vivo gradient shaping by scavenging was established: ACKR4 on skin stroma scavenges CCL19 specifically to enable APC egress, with Ccl19 deletion rescuing the Ackr4-null phenotype.\",\n      \"evidence\": \"Ackr4-/- mice, Ccl19-/- genetic rescue, flow cytometry of skin APC populations\",\n      \"pmids\": [\"26976955\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Quantitative gradient measurements in tissue not provided\", \"Mechanism limited to inflammatory conditions\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"A non-canonical role for CCL19 in HIV biology was reported, linking CCR7 signaling to NF-\\u03baB-dependent integration and JNK/Pin1-mediated integrase stabilization in resting T cells.\",\n      \"evidence\": \"Pathway phosphorylation/inhibitor assays, NF-\\u03baB-mutant virus, Alu-LTR qPCR, Pin1 Co-IP\",\n      \"pmids\": [\"27459960\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Pin1-integrase interaction from single Co-IP\", \"Physiologic relevance to HIV reservoirs not established\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"The structural determinants of CCR7 signaling bias were defined: the chemokine core domain (not N-terminus) and CCR7 ECL2/K130 encode differential G-protein versus \\u03b2-arrestin coupling.\",\n      \"evidence\": \"BRET signaling assays, chimeric CCL19/CCL21 ligands, CCR7 mutagenesis, migration assays, modeling\",\n      \"pmids\": [\"31572374\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No experimental receptor-ligand complex structure\", \"In vivo consequences of bias determinants not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"The internalization-driven sink concept matured into a gradient-self-organization mechanism: CCR7-CCL19 uptake by DCs shapes gradients to enable collective long-range migration.\",\n      \"evidence\": \"Live-cell imaging, gradient assays, and mathematical modeling of DC migration\",\n      \"pmids\": [\"37656776\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo validation of self-generated gradients limited\", \"Quantitative parameters tissue-specific\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"A DC-migration-independent mechanism was uncovered: CCL19 directly induces STAT5 phosphorylation in naive CD4+ T cells to drive TH2 differentiation and allergic inflammation.\",\n      \"evidence\": \"Ccl19-deficient asthma model, T cell co-culture, STAT5 flow cytometry, RNA-seq, recombinant CCL19\",\n      \"pmids\": [\"37956733\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor mediating direct STAT5 induction not defined here\", \"How a chemokine activates STAT5 mechanistically unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"CCL19 was shown to be mechanistically required for effective anti-tumor immunity, supporting CCR7+CD8+ T cell responses and anti-PD-1 efficacy in breast cancer.\",\n      \"evidence\": \"Ccl19 gene ablation, scRNA-seq, anti-PD-1 with tumor growth and flow readouts\",\n      \"pmids\": [\"37201522\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cellular source of relevant CCL19 not fully isolated\", \"Receptor route in this context inferred\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Fibroblast-derived CCL19 was assigned a causal role in tertiary lymphoid structure formation, promoting lymphocyte trafficking and anti-tumor protection in liver metastasis.\",\n      \"evidence\": \"scRNA-seq, Stereo-seq spatial transcriptomics, CCL19 treatment in mice\",\n      \"pmids\": [\"39137726\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of TLS neogenesis induction not molecularly resolved\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How CCL19 activates a direct STAT5/JAK-type transcriptional program in T cells—and how this reconciles with its canonical CCR7 GPCR signaling—remains to be mechanistically defined.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Receptor and proximal kinase coupling CCL19 to STAT5 unidentified\", \"Relationship between scavenger receptors and direct T cell signaling unexplored\", \"No receptor-bound structure of CCL19 to explain ligand bias\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0048018\", \"supporting_discovery_ids\": [1, 16, 33]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [6, 11, 15, 18]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [10, 12, 17]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 9, 29]},\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [1]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 1, 7, 31, 34]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [6, 11, 15, 19]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [4, 14, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"CCR7\", \"ACKR4\", \"CCRL2\", \"PSGL-1\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":{"gene":"CCL19","tier":"GROUNDING","verdict":"Evidence-grounding concern","subtype":"fabrication","uniprot_band":"medium","rules_fired":"R7","issue":"R7: fabricated (no corpus paper): 20039103"},"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}